 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 1 of 75 
 Protocol  
 
Protocol Title:   Dapagliflozin Effect on Symptoms and 
Biomarkers in Patients with Heart Failure  (DEFINE -HF) 
 
Protocol Number:  D1690C00032  
 
ClinicalTrials.gov registration:   [STUDY_ID_REMOVED]  
 
Version Date:    November 4, 2017  
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 2 of 75 
 PROTOCOL SYNOPSIS  
A 12 -week randomized, double -blind, placebo -controlled trial to evaluate  the effects of  once -daily 
dapagliflozin 10 mg on heart failure disease -specific biomarkers  (BNP and NTproBNP) , symptoms, 
health status, and quality of life in patients with chronic heart failure  with reduced systolic function .  
Substudies will also be conducted for explorator y biomarker analys es and effects on arrhythmia  
burden . 
 
Study Hypothesis  
Treatment with dapagliflozin [ADDRESS_132643] site , it is expected that enrollment will take approximate ly 30 months . 
After randomization, dapagliflozin  or placebo will be administered for 12 weeks. Renal function will 
be evaluated 1 week after discontinuation of dapagliflozin or placebo.   
 
Primary Outcome Variable s (two co -primary endpoints will be evaluat ed) 
1. Difference in mean NTproBNP between the treatment and placebo study arms at 6 and 12 
weeks.    
2. Increase of ≥ 5pts in heart failure disease specific quality of life (assessed using the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) summary score) or a ≥  20% decrease in NTproBNP over 
12 weeks.  
Secondary Outcome Variables  
1. Proportion of patients with a ≥ 5pts increase in KCCQ . 
2. Proportion of patients with a ≥ 20% decrease in NTpro BNP . 
3. Proportion of patients with a ≥ 5pts increase in KCCQ and  a ≥ 20% decrease  in NTpro BNP . 
4. Change in KCCQ score over 12 weeks.  
5. Change in 6 minute walk score over 12 weeks.  
6. Change in BNP over 12 weeks.  
7. Change in HbA1c over 12 weeks.  (evaluated separately in patients with and without type 2 
diabetes)  
8. Change in weight over 12 weeks . 
9. Change in systolic blood pressure over 12 weeks . 
Exploratory Outcome Variables  
1. Effects on average weekly loop diuretic dose (furosemide equivalent).  
2. Effec ts on hospi[INVESTIGATOR_104732].  
3. Effects on rate of urgent outpatient heart failure visits . 
4. Effects on the rate of hospi[INVESTIGATOR_118873].  
5. Change in NYHA Class over [ADDRESS_132644] on lung fluid volumes  measured by [CONTACT_118967]™ (SensiVest)  over 
the treatment period  (at selected sites) . 
8. Change in mean lung fluid volumes measured by [CONTACT_118967]™ 
(SensiVest) between week 12 and week 13  (at selected sites)   
 
Safety Variables  
1. All cause death  
2. Cardiovascular  death  
3. Non -fatal myocardial infarction (MI)  
4. Stroke  
5. Acute kidney injur y (defined as doubling of serum creatinine based on the modified RIFLE 
criteria)  
6. Adverse events (AEs) and serious adverse events (SAEs) . AEs of special interest will include DKA, 
volume depletion (defined as hypotension, syncope, orthostatic hypotension or  dehydration ) 
and severe hypoglycemic events.  
 
Statistical Methods  
Baseline demographic and clinical data will be described between treatment and placebo study arms as 
mean ± standard deviation for continuous variables and compared using Student’s T -test. Whereas 
discrete variables will be represented as a number and (%) and compared using the χ2 or Fisher’s exact 
test, as applicable.  
The time course of continuous variables will be presented using standard descriptive summary statistics 
calculated at each scheduled measuring time point and the last individual measuring ti me point. 
Moreover, standard descriptive summary statistics will be calculated for the change (absolute or percent) 
from baseline to each scheduled measuring time point after baseline and the last individual measuring 
time point.  
 
Statistical significance will be defined using two -sided tests with α=0.05 , unless otherwise specified . All 
statistical analyses will be performed by [CONTACT_118968]’s Mid America Heart Institute  Department of 
Biostatistics using SAS version 9.4 (SAS Institute, Cary, North Carolina ). 
The first co -primary endpoint of this study is to compare dapagliflozin versus placebo on mean NTproBNP 
at [ADDRESS_132645] over 6 a nd 12 weeks controlling for baseline NTproBNP . 
Gamma distribution and log link function will be used because of the skewness nature of NTproBNP. 
Center is included as a random factor to account for cluster ing of patients within centers .  
The second co-primary endpoint, proportion of patients with a  ≥ 5 point KCCQ overall summary score  
increase  or a ≥ 20% decrease in NT proBNP  at either [ADDRESS_132646] co -primary endpoint a  sample size of 110 for each group wi ll achieve 80% power with α=0.[ADDRESS_132647] 302 pg/mL from baseline to [ADDRESS_132648] deviation for NTproBNP was 1250 pg/mL. We expect the standard deviation in the 
DEFINE -HF Trial to be somewhat lower (961 pg/ml) given lower N TproBNP threshold. Of note, 302pg/mL 
reduction  in NTproBNP  is equivalent to 31.5% of the standard deviation  in NTproBNP  (based on the 
above assumption) .  
The second co-primary endpoint is a combined endpoint of a ≥ 5 point KCCQ overall summary score 
increa se  or a ≥ 20% decrease in NT proBNP. The sample size was determined using two independent 
groups where the anticipated control group percent change is 30%.  A sample size of 110 for each group 
will achieve 80% power with α=0.[ADDRESS_132649] a difference in pr oportional cha nge between the two 
groups of 1 8% from baseline to 12 weeks for the second co -primary endpoint.    
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 6 of 75 
 Contents  
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ................................ .... 1 
1 INTRODUCTION  ................................ ................................ ................................ ................................ ... 12 
1.1 Background and Significance  ................................ ................................ ................................ ...... 12 
1.2 Research Hypothesis  ................................ ................................ ................................ ...................  13 
1.3 Rationale for conducting this study  ................................ ................................ ............................  13 
1.4 Benefit/risk and ethical assessment  ................................ ................................ ...........................  [ADDRESS_132650] -study treatments  ................................ ................................ ...................  27 
5.7.1  Recording of concomitant medication ................................ ................................ ................  27 
5.8 Treatment Compliance  ................................ ................................ ................................ ...............  27 
5.8.1  Accountability  ................................ ................................ ................................ .....................  27 
5.9 Discontinuations of study medication  ................................ ................................ ........................  27 
5.9.1  General discontinuation criteria  ................................ ................................ .........................  27 
5.9.2  Study -specific di scontinuation criteria ................................ ................................ ................  28 
5.9.3  Procedures for permanent discontinuation of a patient from study medication  ..............  28 
5.9.4  Patient agrees to undergo the Premature Treatment Discontinuation Visit and then 
continue in -person study visits  ................................ ................................ ................................ ...........  28 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 8 of 75 
 5.9.5  Patient refuses to continue in -person study visits but agre es to undergo modified follow -
up……………………………  ................................ ................................ ................................ ..........................  28 
5.9.6  Patient refuses any form of follow -up ................................ ................................ ................  28 
5.9.7  Restart of study medication  ................................ ................................ ................................  28 
5.9.8  Study Closure Visit  ................................ ................................ ................................ ..............  29 
5.10  Withdrawal from study  ................................ ................................ ................................ ...............  29 
5.10.1  Patients permanently discontinuing from study medication  ................................ .............  29 
5.11  Study committees  ................................ ................................ ................................ .......................  29 
5.11.1  Executive Committee  (EC) ................................ ................................ ................................ ... 29 
5.11.2  Steering Committee  ................................ ................................ ................................ ............  30 
5.11.3  Clinical Endpoint Adjudication Committee (CEC) ................................ ................................  30 
5.11.4  Independent Data  and Safety  Monitoring Committee ( IDSMC) ................................ .........  30 
6 Collection of Study Variables  ................................ ................................ ................................ ..............  30 
6.1 Recording of data  ................................ ................................ ................................ ........................  30 
6.2 Data Collection at enrollment and follow -up ................................ ................................ .............  31 
6.2.1  Screening  procedures  ................................ ................................ ................................ ........  31 
6.2.2  Randomization visit (Visit 1)  ................................ ................................ ...............................  32 
6.2.3  Visit 2, 3, 4 and 6 (scheduled telephone contacts)  ................................ .............................  32 
6.2.4  Visit 5 and 7 (on -site visits)  ................................ ................................ ................................ . 32 
6.2.5  Visit 8 (Closeout on -site visit) ................................ ................................ ..............................  33 
6.2.6  Premature Treatme nt Discontinuation Visit (PTDV)  ................................ ...........................  33 
6.3 Patient Monitoring During Study Visits  ................................ ................................ ......................  34 
6.3.1         Patient Monitoring……………………………………………………………………………………… ..…………… .…[ADDRESS_132651] Measurement of Lung Fluid Volume ……………………………………………………………………… 36 
6.7 Collection of Kansas City Cardiomyopathy Questionnaire (KCCQ)  ................................ .............  36 
6.8 Laboratory  safety assessment  ................................ ................................ ................................ ..... 37 
7 Biological Sampling Procedu res ................................ ................................ ................................ ..........  37 
7.1 Volume of blood ................................ ................................ ................................ ..........................  37 
7.2 Handling, storage and destruction of biological samples  ................................ ...........................  37 
8 Safety  ................................ ................................ ................................ ................................ ..................  38 
8.1 Definition of adverse events  ................................ ................................ ................................ .......  38 
8.2 Definitions of serious adverse event  ................................ ................................ ..........................  38 
8.2.1  Classification of Death  ................................ ................................ ................................ ........  38 
8.2.2  Universal classification of Myocardial Infarction (MI)  ................................ ........................  [ADDRESS_132652] data protection  ................................ ................................ ................................ ..............  43 
9.3 Ethics and regulatory review  ................................ ................................ ................................ ...... 44 
9.4 Informed consent  ................................ ................................ ................................ ........................  44 
9.5 Changes to the protocol and informed consent form  ................................ ................................  44 
9.6 Audits and inspections  ................................ ................................ ................................ ................  45 
9.7 Posting of information on clini caltrials.gov………………………………………………………… .……..……… ….45 
10 Study Management by [CONTACT_118969]’s Hospi[INVESTIGATOR_118874]  ................................ ..............................  [ADDRESS_132653] udy ................................ ................................ ................................ ..............  46 
10.4  Source data  ................................ ................................ ................................ ................................ . 46 
10.5  Study agreements  ................................ ................................ ................................ .......................  46 
10.6  Archiving of study documents  ................................ ................................ ................................ .... 46 
10.7  Study timetable and end of study  ................................ ................................ ...............................  46 
11 Data Management by [CONTACT_118969]’s Hospi[INVESTIGATOR_118874]  ................................ ................................  47 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 11 of 75 
 12 Statistical Methods and Sample Size Determination  ................................ ................................ ..........  47 
12.1  Description of analysis sets  ................................ ................................ ................................ .........  47 
12.1.1  Efficacy analysis set  ................................ ................................ ................................ .............  47 
12.1.2  Safety analysis set  ................................ ................................ ................................ ...............  47 
12.2  Methods of statistical analyses  ................................ ................................ ................................ ... 47 
12.2.1  Primary variable  ................................ ................................ ................................ ..................  48 
12.2.2  Secondary variables  ................................ ................................ ................................ ............  48 
12.2.3  Exploratory variables  ................................ ................................ ................................ ..........  49 
12.2.4  Safety variables  ................................ ................................ ................................ ...................  49 
12.2.5  Analysis for safety  ................................ ................................ ................................ ...............  50 
12.3  Determination of sample size  ................................ ................................ ................................ ..... 50 
13 Important Medical Procedures to be Followed by [CONTACT_737]  ................................ ...................  50 
13.1  Medical emergencies and Saint Luke’s Hospi[INVESTIGATOR_118875]  ................................ ..........................  50 
13.2  Overdose  ................................ ................................ ................................ ................................ ..... 51 
13.3  Pregnancy  ................................ ................................ ................................ ................................ .... 51 
14 Biomarker Substudy ……………………………………………………………………………………………………………… ….…. 50 
15 Future Research…………………………………………………………………………………………………………………… ……….50 
16 Arrhythmia Substudy………………………………… ………………………………………………………………………… …….…[ADDRESS_132654] Lung Fluid Volume Measurements ………………………………………………………………………… ….…52 
18 References  ................................ ................................ ................................ ................................ ..........  52 
19 Appendix A: Heart Failure Hospi[INVESTIGATOR_059] /Urgent Outpatient Visits  ................................ .................  55 
20 Appendix B: Kansas City Cardiomyopathy Questionnaire (KCCQ) ……………………… ……… ………… ….…….57 
21 Appendix C: Biomarker Substudy…………………………………………………………………………… .………… ……….…61 
22 Appendix D: Arrhythmia Substudy……………………………………………..…………………………… .….……………....66 
23    Appendix E: SensiVest ReDS™ Technology to Estimate Lung Fluid Volumes…………… ……….…………….72 
24    Appendix F: Signature [CONTACT_119018]………………………………………………… …………… ..………..….[ADDRESS_132655] hoc analysis of PARAGIDM -HF - a contemporary 
clinical trial of patients with heart failure and reduced ejection fraction (HFrEF), even among patients 
who reported no known history of T2DM, 49% had prediabetes, and 21% had unrecognized T2DM based 
on hemoglobin A1c (HbA1c) criteria.[ADDRESS_132656] common 
cardiovascular (CV) complication of T2DM, exceeding t he incidence of myocardial infraction or stroke.[ADDRESS_132657] morbid cardiovascular complication 
of T2DM, with survival of less than 25% over [ADDRESS_132658] among these classes are thiazolidinediones (TZDs)5-7 and, 
possibly, dipeptidyl peptidase (DPP -4), according to results of the SAVOR and EXAMINE clinical trials.8,9  
Other classes of glucose -lowering medications (insulin and sulfonylureas) may lead to weight gain and 
hypoglycemic events10, which potentially impact heart failure symptoms. As a result, evidence -based 
recommendations are currently unavailable for optimal type 2 diabetes or prediabetes mana gement in 
patients with heart failure.  
Sodium glucose cotransporter type 2 inhibitors (SGLT -2i) appear to be the most promising 
therapy to date for patients with HF. While they produce relatively modest HbA1c reduction, SGLT -2i 
exhibit  a novel, entirely in sulin -independent mode of action through increased urinary excretion of 
glucose.[ADDRESS_132659] benefit for reducing HF 
hospi[INVESTIGATOR_118876].11-13 The EMPA -REG OUTCOME trial randomized 7,020 patients with T2DM and 
established CV disease to 10 or 25 mg of empagliflozin vs. placebo. After a median 3. 1 years, 
significantly fewer patients in the empagliflozin group than in the placebo group experienced the 
primary outcome of MACE (10.5% vs. 12.1%), CV -related death (3.7% vs. 5.9%), or all -cause death (5.7% 
vs. 8.3%).13 There was no difference in outcomes between the10 and 25 mg doses of empagliflozin, with 
both dosage being statistically significantly superior to placebo for primary and secondary endpoints. 13 
Though the trial was predominantly of diabetic patients with coronary artery disease (with only 10% of 
patients having known history of HF at baseline), the maj ority of the benefit appeared to be due to the 
highly significant reduction in hospi[INVESTIGATOR_104732] (a 35% relative risk reduction), and 
prevention of HF -related and arrhythmia -related deaths. The relative risk reduction in HHF was 
statistica lly similar between those with and without a history of HF; however, since overwhelming 
majority of patients did not have HF at baseline, this appeared to represent primarily a HF prevention 
effect.[ADDRESS_132660] for SGLT -2i benefit on hospi[INVESTIGATOR_118877], are similar results in the 
Canagliflozin Cardiovascular Assessment Study  (CANVAS Program) . The CANVAS Program was a 
combination of CANVAS, the original canagliflozin cardiovascular safety trial, which was used to gain FDA 
approval in 2013, and a separate CANVAS -R trial, which was combined with CANVAS for the purpose of 
demonstrating cardiovascular benefit. The CANVAS program enrolled a total of 10,142 patients with 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 13 of 75 
 established CVD (65%) or at high risk of CV events (35%), randomized to canag liflozin (100 mg or 300 
mg) or placebo.15 The primary outcome (nonfatal myocardial infarction or stroke, or CV -related death) 
occurred significantly less frequently with canagliflozin than with placebo (26.9 vs. 31.5 per 1000 
patient -years).12 While the reduction in CV and all -cause death with canagliflozin vs. placebo did not 
reach statistically significance , patients in the pooled canagliflozin arm experienced a significant  33% 
relative risk reduction in HHF.12 Real world data from a large multi -national non -interventional study, 
which combined data from well -established registries across 6 countries also supports the notion of a 
class benefit for SGLT -2i and HF outcomes. The CVD -REAL study analyzed over 300,000 T2DM patients 
and compared the HF outcomes in patients being newly initiated on SGLT -2is versus those being started 
on other glucose lowering medications. The main analysis (ma tched 1:1 using propensity score 
methodology), demonstrated a 39% relative risk reduction in HF hospi[INVESTIGATOR_118878] -2i 
use vs. other glucose -lowering drugs.16 These reductions were also observed for the outcome of total HF 
events, and were consistent in patients with and without established HF.17  
While the excitement surrounding SGLT -2is as potential therapeutic class for the management o f HF 
is warranted, many questions remain unanswered. It is unclear if the reduction in heart failure 
hospi[INVESTIGATOR_118879] -2is to date – which is primarily a signal for HF prevention, will also 
translate to a clinical benefit in patients with est ablished HF, including patients with heart failure and 
reduced ejection fraction (HFrEF). Also given that patients without diabetes (including those with 
prediabetes) would also be expected to have some degree of glucosuria with SGLT -2i treatment, and 
that the CV benefits of SGLT -2i appear to be unrelated to either baseline HbA1c or change in HbA1c, it is 
possible that the potentially beneficial effects of SGLT -2i on reducing HHF may translate to those 
without T2DM.18Additionally more questions regarding t he mechanism of action (MOA) through which  
SGLT -2 inhibit ors may produce a benefit on HF remains unclear, and need further clarification.  To 
provide insight into potential beneficial effects of SGLT -2i in patients with HFrEF (with or without DM), 
as well as to explore potential mechanisms behind these effects,  we plan to perform a  randomized 
clinical trial to evaluate the effects of dapagliflozin, on disease -specific heart failure biomarkers, 
symptoms, health status, and quality of life, in pa tients with chronic heart failure  (both with and without 
DM)  with reduced systolic function.  
1.2 Research Hypothesis  
Treatment with dapagliflozin 10 mg daily for 12 weeks will produce greater reductions in  NTproBNP, 
and improve symptoms , and quality of life  as compared with placebo in patients with chronic heart 
failure  with reduced systolic function . 
1.3 Rationale for conducting this study  
This is a Phase IV study that will determine whether dapagliflozin provides a unique benefit to 
patients with  chronic heart failure with reduced systolic function  by [CONTACT_118970]’ heart failure -related symptoms , health status and quality of life . 
1.4 Benefit/risk and ethical assessment  
Dapagliflozin is approved for  the treatment of type [ADDRESS_132661] an established indication for dapagliflozin therapy. 
Although dapagliflozin is currently not approved in patients without diabetes, when dapagliflozin is 
used either as monother apy or in addition to metformin, it does not cause excess hypoglycemia as 
compared with placebo. No additional safety issues (beyond those observed with dapagliflozin in 
patients with Type 2 diabetes) are anticipated in patients without diabetes treated wi th 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 14 of 75 
 dapagliflozin. Accordingly, we consider the benefit/risk balance to patients enrolled in the study to 
be comparable  to that encountered in the usual clinical practice, with no additional ethical concerns.  
Of note, several large cardiovascular outcome tr ials are currently evaluating various SGLT -2i as 
potential therapi[INVESTIGATOR_118880], and include patients with and without diabetes.19-21 
1.4.1 Risk Category   
Considering  dapagliflozin’s mechanism  of action, the previous  clinical  experien ce with dap agliflozin, 
the study’s design featu res (includi ng the inclusion,  exclusion,  and discontinuation  criteria),  and the 
planned  safety procedures,  participation in this  study presents a minimal  and thus  acce ptable  risk to  
the individual  patients  that will be included.  
1.4.[ADDRESS_132662]  been identified  based  upon the 
mechanism  of action,  the preclinical  results,  and the clinical  experien ce to date,  as well  as 
precau tions included  in the Phase  III program to monitor and/or minimize these  risks, are included  in 
the dapagliflozin prescribing information.  
In clinical Phase  III studies, events  suggestive  of U TI were  reported  in a slightly higher proportion  of 
dapagliflozin-treated patients  than  the placebo  group.  Increased  urinary glucose  excretion  may also 
lead  to an increa sed risk of de velopi[INVESTIGATOR_118881].  In Phase  III studies,  the proportions  of 
patients t reated with  dapagliflozin who reported  adverse events that were  indicative of genital 
infection  were higher than those  seen  for placebo.  
In a pooled  analysis of all phase  2b and  [ADDRESS_132663]  cancer or 
bladder  cancer. The significance of these  findin gs is not clear at presen t; however  a causal 
relationship  with  the use of dap agliflozin seems  unlike ly. 
Overall there were no imbalances of liver function  test paramet ers in Phase  III studies.  One subject  
on dap agliflozin [ADDRESS_132664] of dap agliflozin, volume  depletion  (dehydration,  hypovol emia and/or  
hypotension)  is a potenti al concern. In the  clinical program,  from which  subjects  who in  the 
judgment  of inves tigator  may be at risk of dehydration  or volume  depletion  were e xcluded,  very few 
serious events  related  to volume depletion  were reported  and they were equal ly distributed  
between dapagliflozin and placebo groups.  In the  limited  experience  in subjects  with  type [ADDRESS_132665] elevated BNP at baseline, which will further minimize the risk of 
hypovolemic adverse events.  
The U.S. Food and Drug Administration (FDA) recently reported a warning for sodium -glucose 
cotransporter -2 (SGLT2) inhibitors which may lead to ketoacidosis, a serious condition where the 
body produces high levels of blood acids called ketones that may req uire hospi[INVESTIGATOR_059]. At the time 
of this report there were 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, 
or ketosis in patients treated with SGLT2 inhibitors. DKA, a subset of ketoacidosis or ketosis in 
diabetic patients, is a type of acidosis that usually develops when insulin levels are too low or during 
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132666] of the patients had type 2 diabetes and their blood sugar levels, when reported, were only 
slightly increased compared to typi[INVESTIGATOR_118882]. Factors identified in some reports as having 
potentially triggered the ketoacidosis included  major illness, reduced food and fluid intake, and 
reduced insulin dose. Although the risk of euglycemic DKA is estimated to be very low in this study 
(given the short duration of treatment , and the fact that patients with Type 2 diabetes are at lower 
risk for DKA than Type 1 diabetes, and patients without diabetes are likely not at risk for DKA ) all 
patients will be provided with home urine ketone testing kits, and patients will be monitored for 
symptoms of DKA during in -person visits and study -related pho ne calls. Patients will be instructed to 
self-test for urine ketones and directed to the closest emergency department if the urine ketone 
test is more than mildly positive. The instances of DKA (if any) will be closely monitored as SAE of 
special interest by [CONTACT_30967], as well as the Independent Data and Safety Monitoring 
Committee. In addition,  all patients  that have diabetes  in this study will continue  taking  glucose -
lowering medications (other than open -label SGLT -2 inhibitors)  as bac kground  therapy.  These  drugs 
are wide ly used  anti-hyperglycemic treatments  and will  be prescribed according to the approved 
label in patients with known diabetes . 
Dapagliflozin prescribing information states that the drug should not be started in patients with 
eGFR <60.  Per the FDA submission documents the main reason dapagliflozin clinical studies were 
not designed to include patients with eGFR between 30 -45 was b ecause “glycemic efficacy was not 
expected in the absence of adequate renal function.”[ADDRESS_132667], a recent 
secondary analysis from the EMPA -REG Outcome large scale clinical trial of empagliflozin showed 
dramatic reduction in cardiovascular mortality and hospi[INVESTIGATOR_118883] 2 diabetes; patients with eGFR as low as 30 were allowed to be included in that trial.4,5 
Furthermore, in the same trial (EMPA -REG Outcome) marked benefit was observed with 
empagliflozin vs. placebo for clinically important renal endpoints, including doubling of creatinine 
and progression to ESRD.3,[ADDRESS_132668] link between SGLT2 -inhibitors and renal events. The renal safety (and 
in fact nephroprotective effects) of these agents hav e been demonstrated in clinical trials as stated 
above. The safety meta analysis of dapagliflozin trials also showed no evidence for increase in acute 
kidney injury or acute renal failure events.22 
We plan to monitor renal function carefully in the DEFINE -HF study, and doubling of serum  
crea tinine is a safety variable that is being carefully ascertained; fur thermore, all patients in DEFINE -
HF Trial are volume overloaded at baseline given the requirement for significantly elevated 
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132669] so as to monitor  and minim ize any 
of the potenti al health risks to participating patients. This i ncludes careful monitoring of patient’s 
vital signs and laboratory values, and the temporary and if necessary permanent discontinuation of 
investigational product in individual patients in whom a potential health risk or a laboratory 
abnormality of clinical concern has been identified.  Further, in order to ensure the s afety of all 
patients participating in this study, an Independent Data and Safety Monitoring Committee ( IDSMC) will 
be formed that will continuously review safety  data , including the incidence of serious adverse events 
(SAEs), and conduct assessments to ensure the ongoing safety of study patients. The IDSMC 
responsibilities, authorities, and procedures are documented in a n IDSMC charter. The personnel 
involved in the clinical study at Saint Luke’s Hospi[INVESTIGATOR_118884].  
1.4.4 Benefit to Patients  
All patients  will cont inue taking  their  active  background   thera py; although  a direct benefit  from  
randomiz ed treatment cannot  be assu red as one half of patients will  receive  placebo,  those with type 
2 diabetes or prediabetes randomized to  dapagliflozin may obtain better glucose control.  In this  study, the 
dose of  dapagliflozin 10 mg  once  daily was chosen to provide  efficacy in improving heart failure 
symptoms and biomarkers, as well as reducing HbA1c  while  mitigating the potential for AEs, based  on 
previous  clinic al experience.  In addition,  among patients randomized to active drug, dapagliflozin is 
expected  to help  maintain better glucose control  among those type 2 diabetes or prediabetes , decr ease 
body weight (or p revent  weight gain)  as well as help  lower  blood  press ure especial ly in patients  with  
elevated  baseline  blood  pressure. All patients  are also expected  to recei ve some  benefit  in the form  
of increased  medical  care/attention when participating in study procedures, which includes at least [ADDRESS_132670]. 
1.4.6 Conclusion  
Considering the pre-clinical and clinical experience with  dapagliflozin and the precautions included  in 
the study protocol, participation in this study presents a minim al and thus acceptable  risk to  patien ts 
who meet  the inclusion /exclusion  criteria and consent  to take  part in the  study. 
For additional  details  on benefits  and risk, pl ease see the dapagliflozin prescribing information . 
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132671] of dapagliflozin, as compared with placebo, on heart failure disease -specific 
symptoms, health status , quality of life  and biomarkers  in patient s with chronic heart failure  with 
reduced systolic function .  
2.1 Primary Objective   
1. To compare  the mean NTproBNP between the treatment and placebo study arms at 6 and  12 
weeks.  
2. To compare the proportion of patients that achieve a meaningful change from baseli ne in 
quality of life ( ≥ 5pts  increase in KCCQ overall summary score)  or NT proBNP ( ≥ 20% decrease ) 
over 12 week treatment period between dapagliflozin 10 mg and placebo.  
2.1.1 Secondary  Objectives  
a) To compare the p roportion of patients with a ≥ 5pts increase in the Kansas City Cardiomyopathy 
Questionnaire ( KCCQ ) from baseline over 12 weeks  between dapagliflozin and placebo.  
b) To compare the p roportion of patients with a ≥ 20% decrease in NTpro BNP  from baseline over 
12 week s between dapagliflozin and placebo.  
c) To compare the p roportion of patients with both a ≥ 5pts increase in KCCQ and a ≥ 20% 
decrease in NTproBNP  from baseline over 12  week s between dapagliflozin and placebo.  
d) To compare the change in KCCQ score from bas eline over 12 weeks between dapagliflozin and 
placebo.  
e) To compare the c hange in [ADDRESS_132672] score from baseline  over 12  week s between 
dapagliflozin and placebo . 
f) To compare the mean  BNP between dapagliflozin and placebo  at 6 and 12 weeks . 
g) To compare the c hange in HbA1c from baseline to week 12 between dapagliflozin and placebo . 
(evaluated separately in patients with and without type 2 diabetes ) 
h) To compare the c hange in weight from baseline over 12  week s between dapagliflozin and 
placebo.  
i) To compare the c hange in systolic blood pressure from baseline over 12  week s between 
dapagliflozin and placebo.  
2.1.2 Exploratory  objective  
1. To compare the e ffects on average weekly loop diuretic dose (furosemide equivalent ) between 
dapagliflozin and placebo.  
2. To compare the e ffects on hospi[INVESTIGATOR_118885] . 
3. To compare the effects on urgent outpatient heart failure visits between dapagliflozin and 
placebo.  
4. To compare the effects on hospi[INVESTIGATOR_118886].  
5. To compare the change in NYHA Class from baseline over [ADDRESS_132673] on lung fluid volumes measured by [CONTACT_118971]™ 
(SensiVest ) between dapagliflozin and placebo  over the course of 12 weeks  (at selected sites) . 
8. To compare the e ffect on lung fluid volumes measured by [CONTACT_118971]™ 
(SensiVest ) upon discontinuation of dapagliflozin or placebo  (between weeks 12 and 13 ; at 
selected sites ). 
 
2.1.3 Safety  objective s 
To evaluate the safety of dapagliflozin by [CONTACT_118972], non -fatal MI, 
stroke, acute kidney injury, volume depletion, severe hypoglycemic events, laboratory values, pulse, 
blood pressure , ketoacidosis  and physical examination findings.   
Patients will be encouraged to keep a diary and perfor m self -monitoring of blood glucose  (for 
patients with established type 2 diabetes only) and weight  (as prescribed by [CONTACT_118973] ), as well as specifically self-monitor  for symptoms of 
hypoglycemia and documen t severe  hypoglycemic events, (defined as symptomatic events requiring 
external assistance due to severe impairment in consciousness or behavior with a capi[INVESTIGATOR_118887] <54 mg/dL or blood glucose <54 mg/dL) .).   
Patients will be instructed  to contact [CONTACT_118974].  
Patient s will be instructed to contact [CONTACT_118975]/gain 
of more than 5 pounds in a day or an unexplained weight loss/gain of more than [ADDRESS_132674] of care . A follow -up 
visit at week 13 will be performed to evaluate  markers of  renal function.  
3.2 Study Procedures  
At the screening visit , participants will undergo a physical exam (including vital signs and weight 
assessment) , a laboratory panel, including HbA1c , BNP, NTproBNP, and a renal panel will be 
performed to determine study eligibility  (Table 1 : Study Plan ). At the randomization visit, 
participants will undergo a physical exam (including vital signs and weight assessment), laboratory 
testing, including HbA1c , BNP, NTproBNP, and a renal panel, complete the KCCQ , perform a [ADDRESS_132675]  at selected sites .  
Treatment or placebo will be administered for 12 weeks, with follow -up visits at 6 and 12 weeks 
during which a physical exam (including vital signs and weight assessment), labs, KCCQ , a 6-minute 
walk test will be performed,  lung fluid volume will be measured with the SensiVest  (at selected 
sites) , and A Es/SAEs will be recorded . On days 2 and 10, as well as weeks 4 and 9 participants will be 
contact[CONTACT_118976]/SAEs, and encourage c ompliance with the study medication. 
One week after treatment ends, renal function will be evaluated and lung fluid volume will be 
measured with the SensiVest at a follow -up office visit  (at selected sites) . 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 19 of 75 
  
Table 1: Study Plan   
 
  12 –week double -blind 
treatment period   
 
Screening  
Randomization  
  
     
Visit  SJ 1 2 3 4 5 6 7 8 
Weekg) -2 0 2d 10d 4 6 9 12 
PTDV  13 
Office Visit  X X    X  X X 
Phone Visitf)   X X X  X   
Informed consent  X         
Assess eligibility  X X        
Physical Exam a) X X    X  X X 
Vital signs (BP, pulse)  X X    X  X X 
Orthostatic BP, pulse  X X    X  X X 
NYHA Class  X X    X  X X 
Weight X X    X  X X 
Height X         
Body Mass Index  (BMI)m) X X    X  X X 
Waist circumference X X    X  X X 
Medical History  X         
Conco mitant medication  X X X X X X X X X 
Labo ratory ass essments  Xb) X c,k)    X c,k)  X c,k) X d) 
Urine pregnancy  teste) X X    X  X X 
Urine albumin / creatinine 
ratio testi) X X    X  X X 
Dispense Cardiokey  
monitor h) X     X    
[ADDRESS_132676] lung fluid 
measurement at restl)  X    X  X X 
KCCQ   X    X  X  
AEs  X X X X X X X X 
SAEs  X X X X X X X X 
Hospi[INVESTIGATOR_602]  
  X X X X X X X X 
ER Visits  
  X X X X X X X X 
Urgent outpatient  
heart failure visits  X X X X X X X X 
Dispense urine ketone strips  X        
Dispense study medication   X        
Return/ redispense study 
medication       X  X  
Study medication accountability       X  X  
 
a) Physical Exam includes : complete  physical  examination  consisting of  general appe arance, head, eyes, ears,  
nose, thr oat, neck,  cardiovascul ar system,  lungs, abdo men, lymph  nodes, extremities, neurological 
system, skin,  musculoskeletal system, height  (screening only) , weight, pulse, blood pressure,  monitoring 
for volume depletion, and assessment for ketoacidosis (difficulty breathing, nausea, vomiting, abdominal 
pain, confusion, and unusual fatigue or sleepi[INVESTIGATOR_008] ). 
b) Screening laboratory assessment includes HbA1c , BNP, NTproBNP  and renal panel.   
c) Randomization, Week [ADDRESS_132677]-2 and hs-cTnT . 
d) Week 13 l aboratory assessment includes only renal panel.  
e) Only for women  with childbearing potential . 
f) Phone visits include recording any AE or SAE, self -monitoring of weight and blood glucose  (patients with 
established type 2 diabetes only) , and encouraging compliance with study medication . 
g) Visit Windows: There may be up to [ADDRESS_132678] a +/ - 2-day visit window.  Phone Visits have a +/ -1-day visit window.   
h) For patient s that consent  for the arrhythmia monitoring substudy , a CARDIOKEY  holter monitor will be 
dispensed at these visits.  After wearing for 2 weeks, the patient will return the CARDIOKEY  holter 
monitor by [CONTACT_2319].  
i) The urine specimens collected at 0, [ADDRESS_132679] infection 
will be left to t he local investigator or patient’s primary care physician to order a proper screening 
test to evaluate.    
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 21 of 75 
 j) If a patient is a screen failure at the initial screening visit, they may be rescreened on three  additional 
occasion s at the discretion of the inve stigator.  At the rescreening visit, the patient should be 
treated like a new patient and assigned a new subject number and all screening visit procedures  
should be completed, including obtaining informed consent.  
k) Subjects should be resting in the supin e position for at least 5 minutes prior to collection of blood 
samples for biomarkers at Visit 1 (Week 0 Randomization ), Visit 5 (Week 6 ) and Visit 7 (Week 12 ).  
l) The Sensivest test will only be completed on patients  at selected sites, and  with a BMI of [ADDRESS_132680] testing equipment.  
m) Body mass index (BMI  Formula: weight (kg) / [height (m)]2)) will be calculated using the following 
website17: http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/bmi_calculator.html  
 
3.3 Definition of Active Treatment  
Dapagliflozin 10 mg daily + Standard of Care  for heart failure  with reduced systolic function.  
 
3.4 Definition of Control Arm   
Matching Placebo + Stan dard of Care  for heart failure  with reduced systolic function.  
3.5 Overall Study Duration  
Subjects will participate for a total of 13 weeks. It is estimated that the total study duration will be 
30 months.   
 
4 STUDY POPULATION  
Voluntary participation will be sought from patients  with chronic heart failure  with reduced 
systolic function  at outpatient general cardiology and specialized heart failure clinics . Informed 
consent will be obtained from potentially eligible participants  prior to initiating screening visit 
procedures . 
 
4.1 Inclusion criteria  
1. Age > 18  and < 120 at the screening visit  
2. Established dia gnosis of heart failure (for at least 16 weeks prior to the screening  visit) with 
reduced systolic function (LVEF≤40% due to either ischemic or non -ischemic etiology) 
documented by [CONTACT_118977] (echocardiography, nuclear imaging, LV angiography, 
mag netic resonance imaging) within the past [ADDRESS_132681] 24 months is acceptable 
provided there has been no subsequent LVEF measurement above 40%.  
3. No change in diuretic management for 1 week  prior to screening visit  or between the 
screening and randomization visit  
4. NYHA class II or III heart failure symptoms at the screening and randomization visit  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 22 of 75 
 5. BNP ≥100 pg/mL  and/or NT proBNP ≥ 400 pg/mLa)Ŧ at the screening visit  
6. Ability to provide informed consent  prior to initiating screening visit procedures  
4.2 Exclusion  criteria  
1. Decompensated heart failure (hospi[INVESTIGATOR_118888] 30 days prior to 
screening or NYHA class IV heart failure symptoms at screening)  
2. History of t ype 1 diabetes  
3. Estimated glomerular filtration rate (eGFR) < [ADDRESS_132682] 
equation  GFR (mL/min/1.73 m2 ) = 175 x (Scr) -1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if 
African American)18  
4. Admission for an acute coronary syndrome  (ST-elevation MI, non -ST-elevation MI, or 
unstable angina) , percutaneous coronary intervention, or cardiac surgery within 30 days 
prior to the screening visit .  
5. Admission for cardiac resynchronization therapy (CRT ) within 90 days prior to the screening 
visit 
6. Planned cardiovascular revascularization  (percutaneous intervention or surgical)  or major 
cardiac surgery  (coronary artery by[CONTACT_15806], valve replacement, ventricular assist 
device, cardiac transplantation,  or any other surgery requiring thoracotomy)  or CRT within 
the 90 days  after the screening visit.  
7. Participation in any  interventional  clinical trial  (with an investigational drug or device) that is 
not an observational registry  within the 8 weeks  prior to the screening visit . 
8. History of hypersensitivity to dapagliflozin  
9. For women of child -bearing potential: Current or planned pregnancy or currently lactating .   
Women who are surgically sterile or those who are postmenopausal for at least [ADDRESS_132683] agree to use a medically -accepted method of birth control for the 
duration of the study.  Acceptable birth control methods include: (1) surgi cal sterilization 
(such as a hysterectomy or bilateral tubal ligation), (2) progesterone hormonal 
contraceptives (birth control pi[INVESTIGATOR_118889]), (3) barrier methods (such as a condom or 
diaphragm) used with a spermicide, or (4) an intrauterine device (I UD).  Women of child -
bearing potential will have a urine pregnancy test at every clinic visit and it must be negative 
to continue study participation.   
 
10. Life expectancy <1 year  at the screening visit  
11. Patients who are volume depleted based upon physical exa mination  at the time of the 
screening or randomization visit  
12. BNP < 100 pg/mL  and NT proBNP< 400 pg/mL  at the screening visit  £ 
13. Patients currently being treated with any SGLT -2 inhibitor  (dapagliflozin, canagliflozin, 
empagliflozin)  or having received treatment with any SGLT -2 inhibitor within the 12 weeks 
prior to the screening visit.  
14. Avera ge supi[INVESTIGATOR_113046] <[ADDRESS_132684] or current history of bladder cancer   
16. Active Hematuria  
17. Donation of blood or bone marrow 12 weeks prior  to the screening visit  and no planned 
donation s during the study period  
18. Heart failure  due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, 
severe s tenotic valve disease, and HOCM (hypertrophic obstructive cardiomyopathy).  
 Ŧ  For patients with permanent atrial fibrillation  inclusion thresholds will be BNP ≥ 125 pg/mL or 
NTproBNP ≥ 600 pg/mL  
£For patients with permanent atrial fibrillation  exclusion thresholds will be BNP< 125 pg/mL and 
NTproBNP< 600 pg/mL  
[ADDRESS_132685]  
5.1 Restrictions during the study  
Patients should be fasting from all food and beverages  (except water)  at least [ADDRESS_132686] for an office visit.  Patients  shall not be allowed to use any 
prescribed SGLT -2 inhibitors (dapagliflozin, canagliflozin, empagliflozin),  other than the 
investigational product, at any time during the study. Patients shall not be allowed to  donate blood 
or bone marrow at any time during the study.   Patients shall not be allowed to participate in any 
other interventional clinical trial (with  a drug or device) for the duration of the study.  
5.2 Patient enrollment and randomization  
The Principal Investigator [INVESTIGATOR_118890]: 
1. Obtain signed informed consent from the potential patient before any study specific 
procedures are performed  
2. Determine pa tient eligibility  
3. Assign potential patients a sequential  enrollment number  in the form of Site ID and 
enrollment number i .e.: XXX-XXX 
4. Assign enrolled patient a unique randomization code using Sharp Clinical Services 
interactive web response technology system . 
 
If a patient withdraws from participation in the study, then their enrol lment  number cannot be reused. 
Patients can only be randomized into the study once.  
 
5.3 Procedures for randomization  
Sharp Clinical Services will provide a state -of-the-art interactive web response technology s ystem 
(IRT). Sharp ’s IRT is an innovative value -based product for Subject enrollment, randomization, 
capturing clinical data, drug shipments, and managing drug supply.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 24 of 75 
 Sharp ’s IRT  is [ADDRESS_132687] udy inventory for approved 
users.  
Solutions and Services include:  
• 24/7 Operation  
• Site Administration and Tracking  
• Study Drug Distribution and Resupply Management  
Training and User -Materials:  
During system development, Sharp creates a study -specific user manual and Quick Reference Guide 
for the IRT System. Site and client users are trained at investigator meetings or scheduled web -
based training sessions .  
 
5.4 Procedures for handling incorrectly e nrolled or randomized  patients  
Patients who fail to meet the inclusion/exclusion criteria  should not, under any circumstances, be 
enrolled or randomized . There can be no exceptions to this rule.  
The following steps should be taken in the event that a patie nt, who does not meet 
inclusion/exclusion criteria, is found to have been inadvertently randomized  in the study:  
1. The investigator should inform the Saint Luke’s Hospi[INVESTIGATOR_118891]. Ensuring patient safety must always b e the number one priority . 
2. Study treatment must be discontinued in all cases where continued treatment is 
deemed to pose a safety risk to the patient. After a discussion between the study team 
physician and investigator, a decision may be reached that the patient should 
discontinue study medication. The rationale for discontinuing study medication  must be 
clearly documented. The patient should remain in the study for follow up in accordance 
with defined study procedures including follow -up on endpoints  thro ugh the end of t he 
study consistent with the FAS  principle . 
3. In those cases where continuation of study therapy is judged not to present a concern 
related to safety and disease management, the rationale for continuing  study therapy 
must be clearly documente d. The patient should continue follow up in  accordance with 
defined study procedures.  
 
5.5 Blinding and procedures for unblinding the study  
5.5.1 Methods for ensuring blinding  
The treatment allocation in this study will be double blind. Dapagliflozin (1 0 mg) tablets  and 
matching dapagliflozin  placebo tablets will be provided , identical in appearance and with the same 
number , size, and packaging of tablets. Each bottle  will be labe led with a unique bottle  ID number 
that will be used to assign the treatment to the pati ent but will not indicate treatment allocation to 
the investigator.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 25 of 75 
 No member of the extended study team at Saint Luke’s Hospi[INVESTIGATOR_118874] , the E C, the CEC, or 
personnel at investigational centers  will have access to the randomization  scheme during the 
conduct of the study, with the exception  of the Sharp Clinical Services , and the Biostatistics  
department at  Saint Luke’s Hospi[INVESTIGATOR_118874] . 
The IDSMC will have access to the individual treatment codes and will be able to merge the se with 
the collected study data while the study is o ngoing . The IDSMC will review safety data on a periodic 
basis, including the incidence of SAEs, and conduct safety assessments to ensure the ongoing safety 
of study patients. The IDSMC responsibilities, authorities, and procedures will be documented in a 
IDSMC charter. The personnel involved in the clinical study at Saint Luke’s Hospi[INVESTIGATOR_118892]. 
 
5.5.2 Methods for unblinding the study  
Individual treatment codes, indicating the treatment allocation for each randomized  patient, will be 
available to the investigator(s) or pharmacists from the  Sharp Clinical IVR/IWR system . Routines for 
this w ill be describ ed in the Sharp Clinical IVR/IWR system user manual that will be provided to each 
study site . 
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment. The Saint Luke’s Hospi[INVESTIGATOR_118893]  (Mikhail Kosiborod  or delegate ) should be consulted whenever possible prior 
to the investigator breaking the blind. The investigator documents and reports the action to Saint 
Luke’s Hospi[INVESTIGATOR_118874] , without revealing the treatment given to the patient to the Saint 
Luke’s Hospi[INVESTIGATOR_17399] l of Kansas City  staff. The number of individuals at the study site who become aware 
of the treatment status should be kept to an absolute minimum including keepi[INVESTIGATOR_118894]. Treatment with study medication should be continued if con sidered appropriate.  
Saint Luke’s Hospi[INVESTIGATOR_118895] a study drug and that potentially require expedited 
reporting to regulatory authorities. Treatment codes will not be broken for the planned analyses of 
data until all decisions on the evaluability of the data from each individual patient have been made 
and documented.  
 
5.6 Treatments  
5.6.1 Identity of study medication  
 
Table 2  Identity of study medicati on 
Study Medication  Dosage form and strength  Manufacturer  
Dapagliflozin  Bicon vex, diamond shape,  green 
tablet 10 mg (Size: 11 mm) 
 [COMPANY_008]  
Matching placebo  for 
dapaglif lozin 10 mg  Bicon vex, diamond shape,  green 
tablet (Size: 11 mm) [COMPANY_008]  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 26 of 75 
  
5.6.2 Doses and treatment regimens  
At the randomization visit eligible patients will be randomly assigned to 1 of 2 treatments:  
• Dapagliflozin 1 0 mg, administered orally once daily for the 12 weeks.  
• Matching placebo for d apagliflozin [ADDRESS_132688] should  be taken  once daily in the morni ng and at appro ximate ly the same  
time  of the  day during the study period.  Nevertheless  prior  to each office visit, patients with 
established type 2 diabetes  or prediabetes  should  be instructed  not to take  any glucose -lower ing 
medi cation in the  morning  and to abstain from all food and bever ages for 6  hours; however,  drinking  
water is allowed.  On the day of an office visit, investigational product and other concomit ant 
medi cations  will be taken in the morning, after completion  of cer tain required  study proced ures. 
5.6.3 Drug Dispensing Scheme  
At randomization , one  (1) bottle of dapagliflozin [ADDRESS_132689] of care . Subjects will participate for a total of 13 weeks.  
5.6.5 Labeling  
Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local regulatory 
guidelines. The labels will fulfill GMP Annex [ADDRESS_132690] 
the following information:  
• Name [CONTACT_119019] : Saint Luke’s Hospi[INVESTIGATOR_118874]  
• Study drug(s) dosage form, route of administration, and quantity of dosage units  
• Study code  
• Enrol lment code (will be added by [CONTACT_118978])  
• Kit ID  
• Directions for use (For oral use)  
• Storage conditions  
• “for clinical trial use only”  
• “keep out of reach of children”  
5.6.[ADDRESS_132691] -study treatments  
5.7.1 Recording of concomitant medication  
Detailed recording of all concomitant medications will be made at screening, randomization , and all 
subsequent visits. It  will includ e all medication changes , but  glucose lowering  and heart failure 
medications  in particular .  
5.8 Treatment Compliance  
The administration of study medication should be recorded .  All stops of study medication 
prescribed by [CONTACT_118979]. I n addition, any non -prescribed temporary stops 
(>1 week) of study medication should be recorded.  
Missed doses of dapagliflozin  or placebo blinded study medication should not be taken.  I f a dose is 
missed , the next regularly scheduled dose should be taken and should not be doubled.  
 
5.8.[ADDRESS_132692] be recorded. Any discrepancy 
between dispensed and returned study medication should be explained.  
The investigator will retain the returned medication until the termination of the Clinical Study. Then 
the investigator will retur n any unused medication to  Sharp Clinical Services  for destruction of all 
unused study medication.  Saint Luke’s Hospi[INVESTIGATOR_118896]  a patient 
level before medication is returned to Sharp Clinical Services .  
 
5.9 Discontinuations of study medication  
Patients should be discontinued from study medication in the following situations:  
5.9.[ADDRESS_132693]  of the  patient.  
3. Severe  non-compliance  to protocol  as judged  by [CONTACT_41408]/or Saint Luke's Hospi[INVESTIGATOR_118897] . 
4. Risk to patients as jud ged by [CONTACT_3170]. 
5. Incorrectly enro lled patients. 
6. Patient  lost to follow -up. 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 28 of 75 
 5.9.2 Study -specific discontinuation criteria  
• Doubling of  serum  creatinine  above the baseline  value confirmed by a repeated 
measure ment within  one wee k. 
• Recurrent severe  hypoglycemic  events,  defined as ≥2  severe  events (a severe  hypoglycemic 
event is defined as symptomatic events requiring external assistance due to severe 
impairment in consciousness or behavior with a capi[INVESTIGATOR_118898] <54 
mg/dL  or blood glucose <54 mg/dL) . This definition  should  be appli ed after  possible  
contributing  factors  (eg, excessive p hysical  activi ty, dietary  and medication factors ) have  
been excluded  or addressed by [CONTACT_093].  
• Pregnancy confirmed  by a positive  pregnancy test or otherwise  verified.  
 
5.9.3 Procedures for permanent discontinuation of a patient from study medication  
Patients permanently discontinuing study medication should be given conventional therapy, if 
applicable, and should continue routine care visits with their primary physician . 
A patient that decid es to discontinue study medication will always be asked about the reason(s) for 
their desire to discontinue study medication and the presence of AEs (if any). These data will be 
ascertained and documented by [CONTACT_093] .  AEs will be followed up and the patient should 
return all study medications.  
It is essential to collect as much data as possible for all patients throughout the study and especially 
all potential endpoint events. Discontinuation from study medication is n ot the same as complete 
withdrawal from the study (withdrawal of consent), which has a direct impact on the potential 
validity of all study data, and should be avoided whe never possible.  
5.9.4 Patient agrees to undergo the Premature Treatment Discontinuation Vis it and then continue 
in-person study visits  
The patient agrees to undergo the Premature Treatment Discontinuation Visit (PTDV) and  then 
continue in -person study visits according to plan. This is the preferred option and patients who 
discontinue study medic ation will always be asked if they agree to this approach. If agreed, as 
above, the patient will undergo their PTDV at the next scheduled office visit  after the study 
medication is stopped. The patient will continue attending subsequent study visits accord ing to 
schedule (Table 1 ).  
5.9.5 Patient refuses to continue in -person study visits but agrees to undergo modified follow -up 
If the patient refuses to continue in -person study visits, but agrees to undergo modified follow up, 
the in -person PTDV visit should be performed as soon as possible  after the study medication is 
stopped. All subsequent visits until the end of study date will be done as modified follow -ups (eg, 
regular telephone contacts, a contact [CONTACT_118980], or other means) in order to ascertain 
whether any endpoints or safety events had occurred. Such a patient has not withdrawn his/her 
consent or withdrawn from the study.  
5.9.6 Patient refuses any form of follow -up 
If the patient refuses any form of follow -up, he/she officially withdraws from the study and 
withdraws consent. This decision must  be documented . At the end of the study, vital status on all 
such patients will be collected from publicly available sources, in accordance with local regulations.  
5.9.7 Restart of study medication  
Whenever possible, and at every study visit, restart of randomized study medication should be 
encouraged, even if a  PTDV was previously completed.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 29 of 75 
 5.9.8 Study Closure Visit  
All randomized patients should return for their study closure visit  (visit 8) as soon as possible, but no 
later than [ADDRESS_132694] should be made 
to ascertain endpoint and AE information. At the study closure visit , physicians  caring for the patient 
will decide which medication the patient should receive as part of his/her ongoing clinical care.  
5.10 Withdrawal from study  
Patients are at any time free to withdraw from the study (i .e., discontinue study medication 
permanently and wit hdraw from visit assessments), without prejudice to further treatment 
(withdrawal of consent). Withdrawal of consent from the study must be ascertained and 
documented by [CONTACT_093] . Such patients will always be asked about the reason(s) and the 
prese nce of any AEs. The reason for permanent discontinuation of treatment with the study 
medication and the date of the last intake of the study medication must be documented .  
5.10.1  Patients permanently discontinuing from study medication should be given conventional 
therapy, if applicable, and should always be asked to continue to attend protocol visits  
If the patient denies any additional protocol follow -up and officially withdraws consent from the 
study one of the alternatives a) to c) should be follow ed: 
• At the time of discontinuation of treatment and withdrawal of consent from continued 
assessment the patient should, if possible, undergo the PTDV. The patient should return all 
study medication  
• If the patient does not agree to this option (which must b e documented), a modified PTDV 
(eg, a telephone contact) should be arranged. The approach taken should be documented. 
The patient should return all study medication  
• If the patient does not agree to a) or b) this must be documented in the patient’s medical 
record. The patient should return all study medication.  
To ensure validity of study data, it is very important to collect as much data as possible 
throughout the study and especially vital status (dead or alive) at the SCV. The investigator or 
delegate wil l therefore attempt to collect information on all patients’ vital status from publicly 
available sources at the SCV, in accordance with local regulations, even if informed consent has 
been withdrawn completely.  
5.11 Study committees  
5.11.1  Executive Committee  (EC) 
The EC will be responsible for the overall design, including the development of the protocol and any 
protocol amendments, supervision, interpretation and reporting (presentations at international 
congresses and publications in peer reviewed journals) of the s tudy. The E C will make 
recommendations to Saint Luke’s Hospi[INVESTIGATOR_118899]. The E C will be 
comprised of the overall study PI  (EC Chair)  and des ignated academic leaders with expertise in the 
fields of heart failure  and cardiometabolic disease . The precise responsibilities and  procedures 
applicable for the EC will be detailed in a separate EC charter.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 30 of 75 
 5.11.2  Steering Committee  
A steering committee will be  formed and composed of PIs from each participating site . A publication 
plan will be developed with input from this committee.  
 
5.11.3  Clinical Endpoint Adjudication Committee (CEC)  
An independent CEC will be appointed and will adjudicate all heart failure hospi[INVESTIGATOR_602] , urgent 
heart failure visits and major cardiovascular events  (cardiovascular death, myocardial infarction, 
stroke) . The committee members will not have access to individual treatment codes for any patient 
or clinical efficacy  and safety event. The precise responsibilities and procedures applicable for the 
CEC will be detailed in a separate CEC charter.  
 
5.11.4  Independent Data and Safety Monitoring Committee ( IDSMC)  
An independent D SMC will be appointed . 
The IDSMC will be responsible for safeguarding the interests of the patients in the study by [CONTACT_118981], and for reviewing the overall conduct of the clinical 
study. The IDSMC will have access to the individual treat ment  codes and will be able to merge these 
with the collected study data while the study is ongoing.  
The E C and Saint Luke’s Hospi[INVESTIGATOR_118900]. Simila rly, all summary output reviewed at each 
IDSMC meeting will be held in confidence by [CONTACT_118982].  
The IDSMC charter will be prepared to detail precise roles and responsibilitie s and procedures  to 
ensure maintenance of the blinding and integrity of the study in the review of accumulating data 
and interactions with the overall s tudy PI (EC Chair) .  
The IDSMC may elect to request an Interim efficacy and /or futility  analysis at its discretion in 
consultation with the overall study PI (EC Chair).  If this option is elected, the IDSM C charter will be 
amended accordingly.    
 
6 COLLECTION OF STUDY VARIABLES  
6.1 Recording of data  
The REDCap  Web Based Data Capture (WBDC) system will be used for data collection and query 
handling. The site Principal I nvestigator will ensure that data are recorded in the electronic Case 
Report Forms (eCRF) and will ensure the accuracy, completeness, and timelin ess of the data 
recorded and of the provision of answers to data queries according to the Clinical Study Agreement 
(CSA).  
Data will be entered in the eCRF using the REDCap  Web Based Data Capture (WBDC) system by 
[CONTACT_118983].  When d ata have been entered, reviewed, edited, and source 
data verification has been performed , as appropriate , by [CONTACT_118984]’s Hospi[INVESTIGATOR_118901], the data will be frozen to prevent further editing. The site Principal Investigator [INVESTIGATOR_118902] . A copy of the eCRF data will be archived at the study site.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 31 of 75 
  
6.2 Data Collection at enrollment and follow -up 
 
TABLE 3  Laboratory variables  
 
Visit  S 1 2 3 4 5 6 7 8 
Week  -2 0 2d* 10d* 4 6 9 12 13 
HbA1c  X X    X  X  
Glucose  
(included in the 
renal panel)   X    X  X  
BNP  X X    X  X  
NTproBNP  X X    X  X  
Urine albumin 
creatinine Ratio  X X    X  X X 
Urine Pregnancy 
Test X X    X  X X 
CBC   X    X  X  
Renal Panel ** X X    X  X X 
Biomarkers ***  X    X  X  
       *days after randomization                 
                                  ** The renal panel includes albumin, BUN/Creatinine Ratio (calculated), calcium,  
                                       carbon dioxide, chloride, creatinine, estimated glomeru lar filtration rate  
                                       (calculated), glucose,  phosphate (as phosphorus), potassium, sodium, urea  
                                       nitrogen  
     *** uric acid, IL-6, HS -CRP, CML, sRAGE, Gal-3, sST2 and hs-cTnT  
 
 
6.2.1 Screening  Visit P rocedures  (Visit S) 
• Informed consent  
• Blood sampling for  laboratory assessments  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Height  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Urine pregnancy test (only applicable for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Medical history  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 32 of 75 
 • Concomitant medications  
• Dispense C ARDIOKEY  monitor (if participating in the arrhythmia substudy)  
• Contact [CONTACT_118985]  
• Assess e ligibility criteria  
 
 
6.2.2 Randomi zation Visit (Visit 1 )  
Patients that fulfill the eligibility criteria will undergo randomization procedures.  
• Assess e ligibility cr iteria  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  and biomarkers  
• Urine pregnancy test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Dispensed study medication  
• Dispense Urine Ketone Strips  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• [ADDRESS_132695]   
• KCCQ  questionnaire  
• Adverse events  
• Serious adverse events  
• Hospi[INVESTIGATOR_602] , ER visits , urgent outpat ient visits for heart failure  
• Contact [CONTACT_118986]  
• Dispense study medication  
 
6.2.3 Visit 2, 3, 4 and 6 (phone visits ) 
• Concomitant medications  
• Adverse events  
• Serious adverse events  
• Hospi[INVESTIGATOR_602], ER visits, urgent outpatient visits for heart failure  
• Self-monitored weight  
• Self-monitored Blood Glucose  (for patients with established type 2 diabetes)  
• Volume depletion monitoring  
• Ketoacidosis monitoring  
• Encourage compliance with study medication  
 
6.2.4 Visit 5 and 7 (office  visit s) 
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 33 of 75 
 • Fasting b lood sampling for laboratory assessments  and biomarkers  
• Urine pregnanc y test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• [ADDRESS_132696]   
• KCCQ  questionnaire  
• Concomitant medications  
• Adverse events  
• Serious adverse events  
• Hospi[INVESTIGATOR_602], ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monitoring  
• Ketoacidosis m onitoring  
• Dispense C ARDIOKEY  monitor ( only at V isit 5 ( Week 6)) if participating in the arrhythmia 
substudy)  
• Study medication return (redispense only at Visit 5  (Week 6) ) and accountability  
• Contact [CONTACT_118987] 7 for treatment completion  
 
6.2.5 Visit 8 (Study Closure Visit ) 
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  (only for renal panel).  
• Urine pregnancy test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected  sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• Adverse events  
• Serious adverse events  
• Hospi[INVESTIGATOR_602], ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monito ring 
• Ketoacidosis monitoring  
 
6.2.6 Premature Treatment Discontinuation Visit (PTDV)  
• Performed at next on -site visit or as soon as possible  (see section 5.9)  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  
• Urine pregnancy test (only applicable for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medication s 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 34 of 75 
 • SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• [ADDRESS_132697]   
• KCCQ  questionnaire  
• Concomitant medications Adver se events  
• Serious adverse events  
• Hospi[INVESTIGATOR_602], ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monitoring  
• Ketoacidosis monitoring  
• Study medication return  and accountability  
• Contact [CONTACT_118988]  
 
6.3 Patient Monitoring During Study Visits  
6.3.1 Patient Monitoring  
• For patients with established type 2 diabetes with a screening HbA1c of ≤ 7.0% and 
receiving insulin at baseline, it is recommended to reduce total daily insulin dose  by 20%  
at randomization . For patients with established type 2 diabetes with a screening HbA1c 
of ≤ 7.0% and receiving sulfonylurea at baseline, it is recommended to reduce total daily 
sulfonylurea dose by 50%  at randomization , or discontinue sulfonylureas  in patients 
receiving the minimal dose of sulfonylurea at baseline.    
• It is recommend ed that self -monitoring of blood glucose  (SMBG)  values is performed by 
[CONTACT_118989] 2 diabetes and reviewed during the study visits . 
• Review of glucose lowering medications should be performed at all study visits . 
Investigators are strongly encouraged to not titrate glucose -lowering medications 
during the study, unless necessary for patient safety reasons.  
• It is recommended that self -monitoring of weight  is performed by [CONTACT_118990] , with  adjustments in loop diuretic  dose , if appropriate 
for optimization of volume status .  
 
6.3.2 Physical examination  
A physical examination  should  be done  accordi ng to schedule  shown in  Study Plan  (Table 1). 
• A complete  physical  examination  should  include  general appe arance, head, eyes, ears,  
nose, thr oat, neck,  cardiovascul ar system,  lungs, abdo men, lymph  nodes, extremities, 
neurological system, skin,  and mus culoskeletal system. Collection of pulse and blood 
pressure should also be collected as described in section 6.4. The patient should  always be 
evalua ted for the  presence of edema and other signs of volume overload (jugular 
venous distention, rales, ascites, etc).  
• Evaluation of volume depletion , including orthostatic vital signs and other physical exam 
findings consistent with dehydration  
• Evaluat ion for the presence of ketoaci dosis, in patients experiencing signs or symptoms 
of keto acidosis, such as tachypnea or hyperventilation, anorexia, abdominal pain, 
nausea, vomiting, lethargy, or mental status changes ;  administer appropriate testing for 
ketoacidosis and direct patients t o the emergency department if ketoacidosis is 
confirmed.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 35 of 75 
 • Baseline data are collected at Visit  1 and a ny new or aggravated  findi ngs discovered  on 
subsequent  physical examinations  should  be recorded  as AE if  clinical ly relevant . 
 
6.3.3 Phone Visits  
Phone visits should be done according to the schedule shown in Study Plan (Table 1).  
Evaluate possible AE and SAEs, medication usage, self-monitoring of weight and blood glucose  
(in patients with established type 2 diabetes) . 
 
Upon review of self -monitoring of w eight and self-monitoring glucose  (in patients with 
established type 2 d iabetes)  consider adjustments in loop diuretics and glucose -lowering 
medications for optim ization of glucose control (in patients with established type 2 diabetes) 
and volume status  if considered necessary from patient safety standpoint .  
 
6.[ADDRESS_132698] 5 minut es and before blood  samples are taken. Blood pressure (BP) and pulse 
should be measured  three times with at least [ADDRESS_132699]  (6MWT)  
The 6MWT is a practical simple test that requires a [ADDRESS_132700] 
surface in a period of 6 minutes  (the 6MWD). It evaluates the global and integrated responses of all 
the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic 
circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not 
provide specific information on the function of each of the different organs and systems involved in 
exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary 
exercise testing. The self -paced 6MWT assesses th e submaximal level of functional capacity. Most 
patients do not achieve maximal exercise capacity during the 6MWT; instead, they choose their own 
intensity of exercise and are allowed to stop and rest during the test. However, because most 
activities of da ily living are performed at submaximal levels of exertion, the 6MWD may better 
reflect the functional exercise level for daily physical activities.[ADDRESS_132701]  utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military (which  used it to see inside buildings and to find 
survivors among rubble ).  Sensible Medical has adapted the same principles and created a vest that 
when worn sends low -power electromagnetic energy through the lungs, which decipher air content 
from fluid. At selected  DEFINE -HF study sites , patients ’ lung  fluid volume will be measured at rest 
(prior to [ADDRESS_132702]) during randomization (0 weeks), 6, [ADDRESS_132703] at home and readings may  be taken by [CONTACT_118991] s twice a day for the 13  weeks, once 
in the morning (when a patient wake s up) and once at night (when a patient  lies down to sleep).  
 
6.7 Collection of Kansas  City Cardiomyopathy Questionnaire (KCCQ)  
The KCCQ (see appendix B) is a disease -specific health status instrument compose d of [ADDRESS_132704] been 
independently demonstrated to be valid, relia ble, and responsive to clinical change. Scores range 
from 0 to 100. For t he KCCQ overall summary score, a small but clinically meaningful change is 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 37 of 75 
 considered to be ≥ 5 points.13 The patients will fill in PRO ( KCCQ ) paper form under the supervision 
of the site staff.  
 
6.[ADDRESS_132705] ry, hematolo gy, urinalysis and 
biomarker testing will be taken at the times indicated in the Study Plan (see Table 1).  Any additional 
laboratory safety samples taken at the investigator ’s discretion will be analy zed locally.  
It is recommended that patients do not have their baseline diuretics changed based upon  naturietic 
peptide levels, and that the patient’s primary cardiologist be blinded to the BNP and NTproBNP data 
collected throughout the trial. There have been varying r esults with trials of NTproBNP guided 
clinical management of heart failure.  Two randomized clinical trials have shown no clear benefit.23-24  
Given the uncertainty of benefit, neither serial collection nor treatment based upon NTproBNP 
levels are currentl y endorsed by [CONTACT_118992]/AHA guidelines.25  For these reasons, it is recommended  that 
hear t failure medication changes not be made based on naturietic peptide levels.  If a patient is 
clinically symptomatic or endorses signs or symptoms of volume overload, clinical judgment should 
be used and diuretic adjustments made as warranted.   
7 BIOLOGICAL SAMPLING PROCEDURES  
7.1 Volume of b lood  
The total volume of blood that will be drawn from each patient for this study is listed in Table  4 
below. The collection of additional samples is performed locally at the discretion of the investigator 
and recorded in the eCRF as appropriate, thus req uiring additional sample volumes.  
Table 4   Volume of blood to be drawn from each patient  
Assessment  Sample volume 
(mL)  Number of 
Samples  Total Volume (mL)  
HbA1c  4 mL whole blood  4 16 mL  
Glucose  2 mL whole blood  3 6 mL  
BNP  2 mL whole blood  4 8 mL  
NTproBNP  2 mL whole blood  4 8 mL  
CBC  4 mL whole blood  3 12 mL  
Renal Panel /Uric 
Acid  
 4 mL whole blood  5 20 mL  
Biomarkers  (IL-6, 
HS-CRP, CML, 
sRAGE, Gal-3,  
ST-2 and hs-cTnT)  40 mL whole 
blood  3 120 mL  
Total    190 mL 
 
7.2 Handling, storage and destruction of biological samples  
 Blood and urine samples will be processed  by [CONTACT_118993] 
(Quest Diagnostics).  All samples  should  be taken by [CONTACT_118994] -HF Protocol Final v3.[ADDRESS_132706] ry, hematolo gy, and urinalysis samples w ill be disposed after analyses.  The 
residual biomarker sample s will be stored as described in appendix C.   
 
8 SAFETY  
8.1 Definition of adverse events  (AE)  
An AE is the development of an undesirable medical condition or the det erioration of a pre -existing 
medical condition following or during exposure to a pharmaceutical product, whether or not 
considered causally related to the product. An undesirable medical condition can be symptoms (eg, 
nausea, chest pa in), signs (e .g., tach ycardia, enlarged liver) or the abnormal results of an 
investigation (e .g., laboratory findings, electrocardiogram). In clinical studies, an AE can include an 
undesirable medical condition occurring at any time, including run -in or washout periods, even if  no 
study treatment has been administered.   The term AE is used to include both serious and non -
serious AEs.  
8.2 Definitions of serious adverse event  (SAE)  
An SAE  is an AE occurring during any study phase (i .e., run -in, treatment, follow -up), that fulfil ls one 
or more of the following criteria:  
• Results in death  
• Is immediately life -threatening  
• Requires in -patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability or incapacity  
• Is a congenital abnormalit y or birth defect  
• Is an important medical event that may jeopardize the patient or may require medical 
intervention to prevent one of the outcomes listed above.  
Any event of cancer, drug dependency/abuse, laboratory abnormalities fulfilling the Hy’s law 
definition or overdose (defined as the accidental or intentional ingestion of any dose of the 
investigational product that is considered both excessive and medically important) should be 
reported as an SAE using the most relevant SAE criteria, as judged by t he Investigator.  
8.2.1 Classification of Death  
Deaths will be sub -classified by [CONTACT_118995] -CV primary cause. CV death includes sudden cardiac 
death, death due to acute MI, death due to heart failure, death due to a cerebrovascular event, 
death due to other CV ca uses (e .g., pulmonary embolism, aortic disease, CV intervention), and 
deaths for which there was no clearly documented non -CV cause (presumed CV death).  
Additionally, deaths will be sub -classified by [CONTACT_118996] (CHD death) and non -
CHD de ath. CHD death includes Sudden Cardiac Death, Death due to Acute MI, and the subset of 
Death due to other CV Causes that are secondary to a coronary revascularization procedure.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 39 of 75 
 8.2.2 Universal classification of Myocardial Infarction (MI)  
The Third Universal MI definition14 will be used as study specific MI criteria.  
8.2.3 Definition of Stroke  
Stroke is defined as an acute epi[INVESTIGATOR_118903] a central nervous 
system vascular cause. Stroke should be documented by [CONTACT_9661] (eg, CT scan or magnetic resonance 
imaging [MRI] scan). Evidence obtained from autopsy can also confirm the diagnosis. Stroke will be 
sub c lassified, when possible, as either:  
8.2.4 Primary ischemic stroke  
Primary ischemic  stroke is defined as an acute epi[INVESTIGATOR_118904], spi[INVESTIGATOR_1304], or retinal  
dysfunction caused by [CONTACT_118997]. A primary  ischemic stroke may also undergo hemorrhagic transformation (i .e., no 
evidence of hemorrhage  on an initial imaging study, but appearance on a subsequent scan).  
8.2.5 Primary hemorrhagic stroke  
Primary h emorrhagic stroke is defined as an acute epi[INVESTIGATOR_118905] o r global brain, spi[INVESTIGATOR_1304], or 
retinal dysfunction caused by [CONTACT_105] -traumatic intraparenchymal, intr aventricular, or subarachnoid 
hemorrhage as documented by [CONTACT_118998]. Microh emorrhages (<10 mm) evident 
only on MRI are not considered to be a hemorrh agic stroke. Subdural and epi[INVESTIGATOR_118906] h emorrhage, but not strokes.  
8.2.6 Unclassified stroke  
Stroke with unknown etiology will be classified as unclassified stroke if the type of stroke could 
not be determined by [CONTACT_9665].  
8.2.7 Hospi[INVESTIGATOR_118907] a patient is hospi[INVESTIGATOR_118908],  source 
documents will be obtained to adjudicate events . See appendix A for detailed information.  
8.2.8 Urgent outpatient visit s for heart failure  
In the event that a patient requires one or more urgent outpatient visits for heart failure  over 
the course of the study, source documents will be obtained to adjudicate events. See appendix 
A for detailed information  
8.2.9 Acute Kidney Injury  
Acute kidney injury is defined as a doubling of creatinine, consistent with the  modified  RIFLE 
criteria for stage 2 acute kidney injury . 
8.2.10   Ketoacidosis  (DKA)  
Be aware that post  marketing cases show a  possible  association between sodium -glucose 
cotransporter -2 (SGLT2) inhibitor use and the development of a high anion gap metabolic 
acidosis accompanied by [CONTACT_118999] , frequently in the setting of only 
mildly elevated glucose levels (euglycemic DKA) . Investigators are s trongly encouraged to 
instruct p atients and caregivers about the signs and symptoms of keto acidosis, such as 
tachypnea or hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, or mental 
status changes ; evaluate for the presence of ketoacidosis in patients experiencing such signs or 
symptoms  – using provided urine ketone testing kits ; discontinue study medication and advice 
patients to go to the nearest emergency department  if keto acidosis is confirmed; a nd take 
appropriate measures to correct the keto acidosis and to monitor glucose levels.  Investigators 
are also strongly encouraged to avoid concomitant risk factors potentially predisposing to DKA, 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 40 of 75 
 including carbohydrate -restricted diets and marked reducti ons in insulin dose  (for patients with 
established type 2 diabetes)  during the study  among patients receiving insulin at baseline 
(above and beyond reductions in insulin dose specified in the study protocol). Advise patients to 
alert you and seek medical attention immediately if they experience symptoms consistent with 
DKA such as:  nausea, vomiting, abdominal pain, confusion, change in breathing pattern and 
unusual fatigue or sleepi[INVESTIGATOR_008].  
8.2.[ADDRESS_132707].  The risk of volume  depletion  is enhan ced when two 
diuretics  are used in com bination  and in patients  that otherw ise are at risk for vo lume depletion.  
Ther efore, caution should  be exercised  when administeri ng to patients  at risk for volume  
depletion  due to co-existing  conditions  or concomitant  medication s, such as loop diuretics.  These  
patients  should  be carefully mon itored  for volume  status, electro lytes, and renal  function, and 
encouraged to self -monitor weight during the study .  
8.3 Recording of adverse events  
8.3.1 Collection of Adverse  Events  
 AEs and SAEs  (including hospi[INVESTIGATOR_104732]) will be recorded from  Screening 
thro ughout  the treatment period  and includi ng the follow -up period  (Visit  8). 
All AEs/SAEs are to be recorded by [CONTACT_779].   SAEs, DAEs and AEs of Special Interest will be 
captured in the e -CRF.  Non -serious AEs will not be captured in the e -CRF.   
SAEs are defined in section 8.2.  
A drug adverse event (DAE) is an adverse event which leads to premature and permanent 
discontinuation of study medication.   
AEs of Special Interest will include DKA, volume depletion (defined as hypotension, syncope, 
orthostatic hypotension or dehydration) and severe hypoglycemic events.  
Information about a ll urgent outpatient heart failure visits will also be recorded by [CONTACT_119000] e -CRF.  
8.3.2 Follow-up of unreso lved Adverse  Events  
Any AEs that  are unreso lved at the patient’s  last visit in the study are followed up by [CONTACT_119001]. Saint Luke’s Hospi[INVESTIGATOR_118909](s)/SAE(s) at  the end of the  study, if 
judged necessa ry. The requ irement  to follow -up is not int ended to delay database lock or 
production of the clinical study report. Both  these activiti es should  proceed  as plann ed with  
ongoing AEs if  necessa ry. 
Any follow -up of ongoing SAEs after database  lock will be repor ted to Saint Luke’s Hospi[INVESTIGATOR_307] , who 
will no tify the appropriate regulatory authorities of Saint Luke’s Hospi[INVESTIGATOR_118910].  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 41 of 75 
 8.3.3 Variables   
The following  variables will be collected for each AE; 
• AE (verbatim) 
• Date  when t he AE start ed and stopped  
• Maximum  intensity 
• Whether  the AE is  serio us or not  
• Investigator  causality rating against  the Invest igational  Product  (yes or n o) 
• Action  taken  with  regard  to investi gational  product  
• Outcome  
 
In addition,  the following  variables  will be collected for SAEs:  
• Date AE m et criteria for serious AE 
• Date  Invest igator became aware of serious AE  
• AE is  serious due  to 
• Date  of hospi[INVESTIGATOR_059]  
• Date  of disc harge 
• Probable  cause of death 
• Date  of death 
• Autop sy performed  
• Causality assessment in relation to Study procedure(s) 
• Description  of AE  
 
Maximum  intensity will be graded according to the following  rating scale: 
1. mild  (awareness of sign or symptom,  but easily tolerated) 
2. mod erate (discomfort sufficient to cause interference with  normal activiti es) 
3. severe (incapacitating, with inability to perform normal activiti es) 
 
It is important  to distin guish between  serious  and severe  AEs. Severi ty is a measure  of intensi ty. 
An AE of sev ere intensi ty need not necessarily be conside red serious. For example,  nausea  that 
persists  for several  hours may be considered  severe nausea,  but not a SAE. On the  other  hand,  a 
stroke  that results  in only a limit ed degree of disability may be conside red a mild  stroke but 
would be a  SAE. 
8.3.[ADDRESS_132708] and each 
Adverse E vent, and answer ‘yes’ or ‘no’  to the question  ‘Do you consi der that there  is a 
reasonab le possibili ty that the event  may have been caused  by [CONTACT_119002] ?’ 
For SAEs causal relationship  will also be assessed  for other  med ication and study proced ures. 
Note  that for SAEs  that could  be assoc iated  with any study procedu re the causal relationship  is 
implied as ‘yes’. 
8.3.5 Adverse Events based on signs and sy mptoms  
All AEs spontaneous ly reported  by [CONTACT_119003] l: ‘Have  you had any health problems  since  the previous  visit/you were last 
asked?’, or revealed by [CONTACT_119004].  When co llecting AEs, the recording of 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 42 of 75 
 diagnoses  is prefe rred (when poss ible) to recording of a list of signs and symptoms. However, if  a 
diagnosis is known and  there  are other  signs or symptoms that  are not general ly part of the 
diagnosis, the diagnosis  and each sign or symptom  will be recorded separately. 
8.3.[ADDRESS_132709],  
or require  the patient  to receive  specific  corrective  therapy. 
If deterioration  in a laboratory value/vital sign is associated with  clinical signs and symptoms,  the 
sign/symptom will be reported as an AE and the associated laboratory result/vital  sign will be 
considered  as additional  information.  Wherever  possible  the reporti ng inv estigator uses the 
clinical, rather  than the laboratory term (e.g., anemia versus low h emoglobin  value).  In the 
absen ce of clinical  signs or symptoms,  clinical ly relevant deteriorations  in non-mandated  
measu rements  will be reported  as AE( s). 
Any new or aggravated  clinical ly relevant  abno rmal medical  findi ng at a physical examination as 
compared with  the baseline assessment will be report ed as an AE. 
8.3.7 Hypoglyce mic events   
Information about all hypoglycemic events should be collected.  Only severe  hypoglycemic 
epi[INVESTIGATOR_118911] .  A severe  hypoglycemic event is defined as a 
symptomatic event requiring external assistance due to severe impairment in consc iousness or 
behavior  with a capi[INVESTIGATOR_118898] <54 mg/dL.  
8.[ADDRESS_132710] to be reported to Saint Luke’s Hospi[INVESTIGATOR_307] , whether or not considered causally related to 
the investigational product.  The site investigator is responsible for informing the ir local  IRB as per 
local requirements . 
Investigators and other cent er personnel must inform appropriate Saint Luke’s Hospi[INVESTIGATOR_118912] (WBDC) system of any SAE that occurs in the course 
of the study within 1 day (i .e., immediately but no later than the end of the next business day) of 
when he or she becomes aware of it. Follow -up information on SAEs must also be reported by [CONTACT_119005].  
An aut omated email alert will be sent to the designated Saint Luke’s Hospi[INVESTIGATOR_118913], when 
the page with SAE information is saved in WBDC system by [CONTACT_119006]. 
If the WBDC system is not available, then the Investigator or o ther study site personnel reports by 
[CONTACT_119007]’s Hospi[INVESTIGATOR_118913]. A paper back - up SAE report is 
used for this purpose. The same reporting time frames still apply. The investigator is responsible for 
completing the eC RF as soon as the system becomes available again.  
The Saint Luke’s Hospi[INVESTIGATOR_118914]’s Hospi[INVESTIGATOR_118915].  
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 43 of 75 
 8.4.1 Reporting of serious adverse events  to FDA and [COMPANY_008]   
 
The Sponsor (Saint Luke’s Hospi[INVESTIGATOR_118874])  will inform the FDA, via a MedWatch/AdEERs 
form, of any serious or unexpected adverse events that occur in accordance with the reporting 
obligations of [ADDRESS_132711] all such reports to [COMPANY_008] .  A copy 
of the MedWa tch/AdEERs report must be faxed to [COMPANY_008]  at the time the event is reported to 
the FDA.  It is the responsibility of the investigator to compi[INVESTIGATOR_118916] a report according to the FDA reporting require ment timelines and to ensure 
that these reports are also submitted to [COMPANY_008]  at the same time.  
When reporting to [COMPANY_008],  a cover page  should accompany the MedWatch/AdEERs  form 
indicating the following:  
Externally Sponsored Research  (ESR)  
The inv estigator IND number assigned by [CONTACT_119008]’s name [CONTACT_119020]/title and [COMPANY_008] ESR reference number  
Investigative site must also indicate, either in the SAE report or the cover page, the causality  of 
events in relation to  all study medications  and if the SAE is related to disease progression , as 
determined by [CONTACT_458].  
Send SAE report and accompanying cover page by [CONTACT_8307]’s  designated fax line: 
+[PHONE_2704]  
Serious adverse events  that do not require expedited reporting to the FDA need to be reported to 
[COMPANY_008]  preferably using the MedDRA coding language for serious adverse events.   
In the case of blinded trials, [COMPANY_008]  may  request that the Sponsor either provide a copy of th e 
randomization code/ code break information or unblind those SAEs which require expedited 
reporting.  
All SAEs will be reported to [COMPANY_008] , whether or not considered causally related to the 
investigational product.  All SAEs will be documented.   
 
[ADDRESS_132712] their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice (GCP), applicable 
regula tory requirements and the Saint Luke’s Hospi[INVESTIGATOR_118917].  
9.[ADDRESS_132713] data protection  
The Informed Consent Form will incorporate (or, in some cases, be accompanied by a separate 
document incorporating) wording that complies with relev ant data protection and privacy 
legislation.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 44 of 75 
 9.3 Ethics and regulatory review  
An Ethics Committee/Institutional Review Board (IRB) should approve the final study protocol, 
including the final version of the Informed Consent Form and any other written informati on and/or 
materials to be provided to the patient. The investigator/Head of the study site will ensure the 
distribution of these documents to the applicable Ethics Committee/IRB, and to the study site staff.  
The opi[INVESTIGATOR_118918]. The investigator should submit a 
notification of direction/determination as well as a copy of the IRB written approval to Saint Luke’s 
Hospi[INVESTIGATOR_118919].  
The Ethics Committee/IRB shoul d approve all advertising used to recruit patients for the study.  
Saint Luke’s Hospi[INVESTIGATOR_118920].  
If required by [CONTACT_427], the protocol should be re -approved by [CONTACT_119009].  
Saint Luke’s Hospi[INVESTIGATOR_118921]  (as applicable) , Ethics 
Committees/IRB and Principal Investigators with safety updates/reports according to local 
requirements, including S[LOCATION_003]Rs (Suspected Unexpected Serious Adverse Reactions), where 
relevant.  
Each Pri ncipal Investigator is responsible for providing the ir Ethics Committees/IRB with reports of 
any serious and unexpected adverse drug reactions that occur with the study medication  during the 
study, according to their local Ethics Committee/IRB regulations .  
9.4 Informed consent  
The Principal Investigator [INVESTIGATOR_118922]: 
• Ensure each patient is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study  
• Ensure each patient is notified tha t they are free to discontinue from the study at any time  
• Ensure that each patient is given the opportunity to ask questions and allowed time to 
consider the information provided  
• Ensure each patient provides signed and dated informed consent before conduct ing any 
study specific procedure  
• Ensure the original, signed Informed Consent Form(s) is/are stored in the   
Investigator’s Study File  
• Ensure a copy of the signed Informed Consent Form is given to the patient  
• Ensure that any incentives for patients who part icipate in the study as well as any provisions 
for patients harmed as a consequence of study participation are described in the informed 
consent form that is approved by [CONTACT_75399].  
9.5 Changes to the protocol and informed consent form  
Study procedure s will not be changed withou t the mutual agreement of the E C and Saint Luke’s 
Hospi[INVESTIGATOR_118874] . 
If there are any substantial changes to the study protocol, then these changes will be documented in 
a study protocol amendment and where required in a n ew version of the study protocol (Revised 
Clinical Study Protocol).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 45 of 75 
 Saint Luke’s Hospi[INVESTIGATOR_118923](s). If a protocol amendm ent requires a change  to a site’s 
Informed Consent Form, Saint Luke’s Hospi[INVESTIGATOR_118924]’s IRB are to approve the 
revised Informed Consent Form before the revised form is used.  
Any administrative change (s) and protocol amendment(s)  will be prepared and approv ed by [CONTACT_91332] ( Saint Luke’s Hospi[INVESTIGATOR_307] ) and subsequently communicated to  the E C. 
9.6 Audits and inspections  
Authorized  representatives of Saint Luke’s Hospi[INVESTIGATOR_118874] , a regulatory authority, or an 
Ethics Committee may perform audits or inspect ions at the cent er, including source data 
verification. The purpose of an audit or inspection is to systematically and independently examine all 
study - related activities and documents, to determine whether these activities were conducted, and 
data were re corded, analyzed , and accurately reported according to the protocol, GCP, guidelines of 
the International Conference on Harmonization  (ICH), and any applicable regulatory requirements. 
The investigator will contact [CONTACT_118969]’s Hospi[INVESTIGATOR_118925] a 
regulatory agency about an inspection at the cent er. 
9.7 Posting of information on clinicaltrials.gov  
Study information from this protocol will be posted on clinicaltrials.gov before  enrollment of 
patient s begins.  
 
10 STUDY MANAGEME NT BY [CONTACT_119010]’S HOSPI[INVESTIGATOR_118926]  
10.[ADDRESS_132714] patient is entered into the study, it is necessary for a representative of  Saint Luke’s 
Hospi[INVESTIGATOR_118927]:  
• Determine the adequacy of the facilities  
• Determine availability of appropriate patients for the study  
• Discuss with the investigator(s) (and other personnel involved with the study) their 
responsibilities with regard to p rotocol adherence, and the responsibilities of Saint Luke’s 
Hospi[INVESTIGATOR_118928]. This will be documented in a Clinical Study 
Agreement between Saint Luke’s Hospi[INVESTIGATOR_118929].  
10.[ADDRESS_132715] patie nt is entered into the study, a  Saint Luke’s Hospi[INVESTIGATOR_118930](s) utilized.  
The Principal Investigator [INVESTIGATOR_118931], and that any new information relevant to the performance of this study  is forwarded to 
the staff involved.  
The Principal Investigator [INVESTIGATOR_17459] a record of all individuals involved in the study  (medical, 
nursing and other staff).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 46 of 75 
 10.3 Monitoring of the study  
During the study, a  Saint Luke’s Hospi[INVESTIGATOR_118932] .  The  monitoring visits may be conducted by [CONTACT_648], e -mail or by 
[INVESTIGATOR_2993]-person visits to the study site.  The monitoring visits  will: 
• Provide information and support to the investigator(s)  
• Confirm th at facilities remain acceptable  
• Confirm that the investigational team is adhering to the protocol, that data are being accurately 
and timely recorded in the eCRF and that study drug accountability checks are being performed  
• Perform source data verification  (a comparison of the data in the eCRF with the patient’s 
medical records at the hospi[INVESTIGATOR_7117], and other records relevant to the study) including 
verification of informed consent of participating patients.  
 
The Saint Luke’s Hospi[INVESTIGATOR_118933](s) or other study site personnel need information and advice about the study conduct.  
10.4 Source data  
The Clinical Study Agreement (CSA) will specify the location of source data.  Access to so urce 
documents and source data is essential to inspection and review of clinical studies by [CONTACT_4469] (FDA).  
10.[ADDRESS_132716] or treatment of patients, the terms of the CSA shall prevail.  
Agreements between Saint Luke’s Hospi[INVESTIGATOR_118934] -related procedures can take place, or patients are enrolled.  
10.6 Archiving of study documents  
The Investigator follows the principles outlined in the CSA.  
10.7 Study timetable and end of study  
The study is expected to start  in March 2016  and t o end in May 2017 . Planned  treatment du ration in 
the study is 13 weeks.  Saint Luke’s Hospi[INVESTIGATOR_118935].  The end of the entire study is defined as ‘the last visit of the last p atient undergoing the 
study’.  
The study may be terminated at individual centers  if the study procedures are not being performed 
according to GCP, or if recruitment is slow. Saint Luke’s Hospi[INVESTIGATOR_118936] y if concerns for safety arise within this study or in any other study with 
dapagliflozin . 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 47 of 75 
 11 DATA MANAGEMENT BY [CONTACT_119010]’S HOSPI[INVESTIGATOR_118937]’s Hospi[INVESTIGATOR_118938] r staff. Data will be entered in the WBDC system at the study site. Trained site staff will be  
responsible for entering data on the observations, tests and assessments specified in the  protocol 
into the WBDC system . Data entered in th e WBDC system will be immediately saved to a central 
database and changes tracked to provide an  audit trail. The data will then be source data verified, 
reviewed/queried and updated as needed. The Principal Investigator [INVESTIGATOR_118939]. Data queries will be raised for inconsistent, improbable  or missing data. All entries 
to the study database will be available in an audit trail. The data will be frozen and then locked to 
prevent further editing. When all data have been c oded, validated, signed, and locked, a clean file 
will be declared. Any treatment revealing data may thereafter be added and the final database will 
be locked. A copy of the eCRF will be archived at the study site when the study has been locked.  
 
12 STATISTIC AL METHODS AND SAMPLE SIZE DETERMINATION  
12.1 Description of analysis sets  
12.1.1  Efficacy  analysis set  
Intention to treat (ITT) is defined as a ll patients who have been randomized to study treatment 
and completed at least one follow -up where the KCCQ and NTproBNP are collected. The ITT data 
set will be used for the primary and secondary efficacy endpoints and exploratory endpoints.  
12.1.[ADDRESS_132717] -dose data are avai lable, will be included in the safety analysis set. Throughout the safety 
results sections, erroneously treated patients (eg, those randomized to dapagliflozin  but actually 
given placebo) will be accounted for in the actual treatment group. If a patient re ceived study 
drug from the wrong kit for only a part of the treatment duration and then switched to another, 
the associated actual treatment group for that patient will be the treatment group the patient 
had the longest exposure to.  
12.2 Methods of statistical analyses  
All analyses will be on the ITT  unless otherwise specified. Baseline demographic and clinical data will 
be described between treatment and placebo study arms as mean ± standard deviation for 
continuous variables  and compared using Student’s T -test. Whereas discrete variables will be 
represented as a number and (%) and compared using the χ2 or Fisher’s exact test, as applicable .  
The time course of continuous variables will be presented using standard descriptive summary 
statistics calculated at eac h scheduled measuring time point and the last individual measuring time 
point. Moreover, standard descriptive summary statistics will be calculated for the  change (absolute 
or percent) from baseline to each scheduled measuring time point after baseline and  the last 
individual measuring time point.  
 
Due to the large number of study sites  and the expected low number of patients per site it will not 
be appropriate to explore site effects.  
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 48 of 75 
 Statistical significance will be defined using two -sided tests with α=0.05 , unless otherwise specified . 
All statistical analyses will be performed by [CONTACT_118968]’s Mid America Heart Institute  Department 
of Biostatistics  using SAS version 9.4  (SAS Institute, Cary, North Carolina).  
12.2.1  Primary variable  
There are two  co-primary efficacy endpoint s: 
1. Difference in mean NTproBNP between the treatment and placebo study arms at 6 and 12 
weeks.  
2. Proportion of patients that achieve a meaningful change from baseline in quality of life ( ≥ 5pts  
increase in KCCQ overall summary score)  or NT proBNP ( ≥ 20% decrease ) over [ADDRESS_132718] over 6 and 12 weeks cont rolling for baseline NTproBNP . Gamma distribution 
and log link function will be used because of the skewness nature of NTproBNP. Center is included as a 
random factor to account for clustering of patients within centers.  
The second co -primary endpoint, proportion of patients with a  ≥ 5 point KCCQ overall summary score  
increase or a ≥ 20% decrease in NT proBNP  at [ADDRESS_132719] 
controlling for center.  
Both co -primary endpoints will be analyzed in the entire patie nt cohort, and then within the subgroups 
of patients with and without diabetes (as pre -specified subgroup analyses).  
 
 
Statistical significance will be determined using an ordered te sting procedure ; the alpha w ill be 0.05 
for hypothesis 1. If hypothesis  1 is rejected then hypothesis 2 will be tested  at α=0.[ADDRESS_132720] been identified:  
3. Proportion of patients with a ≥ 5pt s increase in KCCQ  over 12 weeks  
4. Proportion of patients with a ≥ 20% decrease in NTproBNP  over 12 weeks  
5. Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP  over 
12 weeks  
6. Change in KCCQ score over 12 weeks.  
7. Change in 6 min ute walk score over 12 weeks.  
8. Difference in mean  BNP at 6 and  12 weeks.  
9. Change in HbA1c over 12 weeks.   (evaluated separately in patients with and without type 2 
diabetes)  
10. Change in weight over 12 weeks  
11. Change in systolic blood pressure over 12 weeks  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 49 of 75 
 For secondary analyses proportional comparisons will be analyzed using the same testing method 
as the primary analyses. For continuous variable comparisons an analysis of covariance (ANCOVA) 
model including terms for treatment group and baseline covariate.  The ANCOVA model will be 
used to derive the treatment difference with 95% confidence interval and corresponding two -
sided p -value. Additionally, the mean change within each treatment group will be calculated with 
corresponding 95% confidence intervals.  
Secondary endpoints will be analyzed in the entire patient cohort, and then within the subgroups of 
patients with and without diabetes (as pre -specified subgroup analyses).  
 
12.2.[ADDRESS_132721] been identified:  
1. Effects on average weekly loop diuretic dose (furosemide equivalent).  
2. Effects on the rate of hospi[INVESTIGATOR_104732].  
3. Effects on rate of urgent outpatient heart failure visits . 
4. Effects on the rate of hospi[INVESTIGATOR_118940] . 
5. Change in NYHA Class over [ADDRESS_132722] on lung fluid volumes measured by [CONTACT_118971]™ ( SensiVest ) over the 
treatment period . 
8. Change in mean lung fluid volumes measure d by [CONTACT_119011]™ (SensiVest ) 
between week 12 and week 13 . 
Exploratory data will be summarized descriptively and presented by [CONTACT_1570].  Exploratory 
endpoints will be analyzed in the entire patient cohort, and then within the subgroups of patients with 
and without diabetes (as pre -specified subgroup analyses).  
 
12.2.[ADDRESS_132723] been identified a priori : 
1. All cause death  
2. Cardiovascular death  
3. Non -fatal myocardial infarction (MI)  
4. Stroke  
5. Acute kidney injury (defined as doubling of serum creatinine based on the RIFLE criteria)  
6. Volume Depletion  
7. Severe hypoglycemic events  
8. Ketoacidosis  
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132724] co -primary endpoint a sample size of 110 for each group will achieve 80% power with α=0.[ADDRESS_132725] 302  pg/mL from baseline to [ADDRESS_132726] deviation for NTproBNP was 1250 pg/mL. We expect the standard deviation in the 
DEFINE -HF Trial to be somewhat lower (961 pg/ml) given lower NTproBNP threshold. Of note, 302pg/mL 
reduction in NTproBNP is equivalent to 31.5% of the standard deviation in NTproBNP (base d on the 
above assumption).  
The second co -primary endpoint is a combined endpoint of a ≥ 5 point KCCQ overall summary score 
increase  or a ≥ 20% decrease in NT proBNP. The sample size was determined using two independent 
groups where the anticipated contro l group percent change is 30%.  A sample size of 110 for each group 
will achieve 80% power with α=0.[ADDRESS_132727] a difference in proportional change between the two 
groups of 1 8% from baseline to 12 weeks for the second co -primary endpoint.  
There is an ant icipated loss to follow -up of approximately 13 % so the final s ample size per group will 
be 125 . 
13 IMPORTANT MEDICAL PROCEDURES TO BE FOLLOWED BY [CONTACT_119012]  
13.1 Medical emergencies and Saint Luke’s Hospi[INVESTIGATOR_118941]. A medical emergency usually constitutes an SAE and 
is to be reported as such . 
In the case of a medical emergency the investigator may contact [CONTACT_119013] y Team Physician at  Saint 
Luke’s Hospi[INVESTIGATOR_118874] . 
 
 
Name  [CONTACT_119021] & telephone number  
Mikhail Kosiborod , MD  Lead Study Team Physician 
responsible for the protocol  Saint Luke’s Hospi[INVESTIGATOR_118874]  
4401 Wornall R oad 
Kansas City, MO [ZIP_CODE]  
Email: Phone: 816 -932-3445  
Cell:  [PHONE_2705]  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 51 of 75 
 Sheryl Windsor, MBA, MT(ASCP)  Study Manager  Saint Luke’s Hospi[INVESTIGATOR_118874]  
4401 Wornall R oad 
Kansas City, MO [ZIP_CODE]  
Email:  
Phone: 816 -932-9858  
Cell: [ADDRESS_132728] 
that is considered both excessive and medically important. Dapagliflozin has been well tolerated at 
doses of up to 500 mg/day in single dose testing in he althy volunteers and up to 100 mg/day in 
repeat dose testing for [ADDRESS_132729] 
inform appropriate Saint Luke’s Hospi[INVESTIGATOR_118942].  
 
[ADDRESS_132730] of dapagliflozin  
versus placebo on known markers of myoca rdial fibrosis/necrosis, inflammation, and oxidative stress .  
Detailed collection, processing, storage and shipment instructions are provided in the central laboratory 
manual.   Information regarding the biomarker substudy is included in appendix C.  
 
[ADDRESS_132731] utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military who used it to see inside buildings and to find survivors 
among rubble.  Sensible Medical has ad apted the same principles and created a vest that when worn 
sends low -power electromagnetic energy through the lungs, which decipher air content from fluid19. 
Two sensors are attached to the body: one anteriorly on the chest and the other on the back of th e 
patient. Each sensor both transmits and receives the energy either reflected from or transferred through 
the pulmonary tissue. The signal received reflects the dielectric properties of the section of the lung 
between the sensors.  Water has a very high d ielectric coefficient while air in contrast has the lowest 
dielectric coefficient. These physical properties make pulmonary tissue ideal to sensitively quantify the 
ratio of fluid to air (or in the case of heart failure estimate volume status and pulmonary  edema).[ADDRESS_132732]  blinded  lung/fluid volume measure ments  at 
rest during the randomization  (week 0) , 6, [ADDRESS_132733] measurement results; de -identified and blinded Sensivest measurements will be accessible 
to th e National Coordinating Center staff.  (See appendix E for further details).  
 
18 REFERENCES  
1. Go, A. S.  et al.  Heart disease and stroke statistics --2014 update: a report from the American 
Heart Association. Circulation  129 , e28 -e292, doi:01.cir.[PHONE_2706].[ZIP_CODE].80 [pii]  
10.1161/01.cir.[PHONE_2706].[ZIP_CODE].80 (2014).  
2 McMurray, J. J.  et al.  Angiotensin -neprilysin inhibition versus enalapril in heart failure. N 
Engl J Med  371 , 993 -1004, doi:10.1056/NEJMoa1409077 (2014).  
3 Parving, H. -H. et al.  Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New 
England Journal of Medicine  367 , 2204 -2213, doi:10.1056/NEJMoa1208799 (2012).  
4 Bertoni, A. G.  et al.  Heart failure prevalence, incidence, and mortality in the elderly with 
diabetes. Diabetes Care  27, 699 -703 (2004).  
5 Erdmann, E.  et al.  Pi[INVESTIGATOR_118943] 2 diabetes and 
preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes 
Care  30, 2773 -2778, doi:dc07 -0717 [pii]  
10.2337/dc07 -0717 (2007).  
6 Komajda, M.  et al.  Heart  failure events with rosiglitazone in type 2 diabetes: data from the 
RECORD clinical trial. Eur Heart J  31, 824 -831, doi:ehp604 [pii]  
10.1093/eurheartj/ehp604 (2010).  
7 Ryden, L., Thrainsdottir, I. & Swedberg, K. Adjudication of serious heart failure in pa tients 
from PROactive. Lancet  369 , 189 -190, doi:S0140 -6736(07)[ZIP_CODE] -8 [pii]  
10.1016/S0140 -6736(07)[ZIP_CODE] -8 (2007).  
8 Scirica, B. M.  et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes 
mellitus. N Engl J Med  369 , 1317 -1326, doi:10 .1056/NEJMoa1307684 (2013).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 53 of 75 
 9 White, W. B.  et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 
N Engl J Med  369 , 1327 -1335, doi:10.1056/NEJMoa1305889 (2013).  
10 Gerstein, H. C.  et al.  Long -term effects of intensive glucose low ering on cardiovascular 
outcomes. N Engl J Med  364 , 818 -828, doi:10.1056/NEJMoa1006524 (2011).  
11 Inzucchi, S. E.  et al.  SGLT -2 inhibitors and cardiovascular risk: proposed pathways and 
review of ongoing outcome trials. Diab Vasc Dis Res  12, 90-100, 
doi:10 .1177/1479164114559852 (2015).  
12 Neal, B.  et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New 
England Journal of Medicine  0, null, doi:10.1056/NEJMoa1611925.  
13 Zinman, B.  et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 
N Engl J Med , doi:10.1056/NEJMoa1504720 (2015).  
14 Fitchett, D.  et al.  <div xmlns=" http://www.w3.org/1999/xhtml  failure outcomes with 
empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the 
EMPA -REG OUTCOME<sup>®</sup> trial</div>. European Heart Journal , 
doi:10.1093/eurheartj/ehv728 (2016).  
15 Neal, B.  et al.  Rationale, design, and baseline characteristi cs of the Canagliflozin 
Cardiovascular Assessment Study (CANVAS) —a randomized placebo -controlled trial. Am 
Heart J  166 , doi:10.1016/j.ahj.2013.05.007 (2013).  
16 Kosiborod, M.  et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT -2 
Inhi bitors Versus Other Glucose -Lowering Drugs: The CVD -REAL Study. Circulation , 
CIRCULATIONAHA. 117.029190 (2017).  
17 Scheerer, M.  et al.  Gesamtereignisraten für die Hospi[INVESTIGATOR_118944] (HHI) 
bei Neueinstellung auf SGLT -2-Hemmer im Vergleich  zu anderen Antidiabetika –Daten aus 
dem klinischen Alltag aus Deutschland, Schweden und Norwegen mit mehr als 45.000 Typ 2 
Diabetes Patienten (CVD -Real). Diabetologie und Stoffwechsel  12, LB12* (2017).  
18 Inzucchi, S. E.  et al.  SGLT -2 inhibitors and cardio vascular risk: proposed pathways and 
review of ongoing outcome trials. Diab Vasc Dis Res  12, doi:10.1177/1479164114559852 
(2015).  
19 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection 
Fraction (EMPEROR -Reduced). ClinicalTrials.gov 2017; 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03057977&rank=1  
20 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved 
Ejection Fraction (EMPEROR -Preserved). ClinicalTrials.gov 2017; 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03057951&rank=[ADDRESS_132734] of Dapagliflozin on the Incidence of Worsening Heart Failure or 
Cardiovascular Death in Patients With Chronic Heart Failure (Dapa -HF). ClinicalTrials.gov 
2017; https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03036124&rank=1  
22 Kosiborod, M., Gause -Nilsson, I., Sonesson, C. & Johnsson, E. in DIABETOLOGIA.   S368 -S368 
(SPRINGER [ADDRESS_132735], NEW YORK, NY [ZIP_CODE] [LOCATION_003]).  
23 Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pi[INVESTIGATOR_118945] A, Yandle TG, Hamid 
AK, Nicholls MG and Richards AM. N -terminal pro -B-type natriuretic peptide -guided 
treatment for chronic heart failure: results from the BATTLESCARRED (NT -proBNP -
Assisted Tr eatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll 
Cardiol . 2009;55:53 -60. 
24 Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, 
Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, H ilti P, Schindler R, 
Brunner -La Rocca HP and Investigators T -C. BNP -guided vs symptom -guided heart failure 
therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With 
Congestive Heart Failure (TIME -CHF) randomized trial. JAMA . 2009;301:383 -92 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 54 of 75 
 25 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, 
Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, 
McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW,  Tang WH, Tsai EJ, 
Wilkoff BL, American College of Cardiology F and American Heart Association Task Force on 
Practice G. 2013 ACCF/AHA guideline for the management of heart failure: a report of the 
American College of Cardiology Foundation/American Heart A ssociation Task Force on 
Practice Guidelines. J Am Coll Cardiol . 2013;62:e147 -239 
 
 
 
 
  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 55 of 75 
 19 APPENDIX A: HEART FAILURE HOSPI[INVESTIGATOR_55108] /URGENT OUTPATIENT VISIT  
A Heart Failure Event includes hospi[INVESTIGATOR_118946]. 
Heart failure  hospi[INVESTIGATOR_118947].  
 
A Heart Failure Hospi[INVESTIGATOR_118948] a: 
 
• The patient is admitted to the hospi[INVESTIGATOR_4791] a primary diagnosis of heart failure  
• The patient’s length -of-stay in hospi[INVESTIGATOR_118949] 24 hours (or a change in calendar 
date if the hospi[INVESTIGATOR_118950])  
• The patient exhibits documented new or worsening symptoms due to heart failure on 
presentation, including at least ONE  of the following:  
 
o Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal 
dyspnea)  
o Decreased exercise tolerance   
o Fatigue  
o Other symptoms of worsened end -organ perfusion or volume overload  
 
• The patient has objective evidence of new or worsening heart failure , consisting of at least TWO  
physical examination findings OR one physical examination finding and at least ONE  laboratory 
criterion), including:  
 
o Physical examination findings considered to be due to heart failure, including new or 
worsened:  
▪ Peripheral edema  
▪ Increasing abdominal distention or ascites (in the absence of primary hepatic 
disease)  
▪ Pulmonary rales/crac kles/crepi[INVESTIGATOR_814]  
▪ Increased jugular venous pressure and/or hepatojugular reflux  
▪ S3 gallop  
▪ Clinically significant or rapid weight gain thought to be related to fluid  retention  
 
o Laboratory evidence of new or worsening heart failure , if obtained within 24 hou rs of 
presentation, including:  
▪ Increased B -type natriuretic peptide (BNP)/ N -terminal pro -BNP (NT - proBNP) 
concentrations consistent with decompensation of heart failure (such as BNP > 
500 pg/mL or NT -proBNP > 2,000 pg/mL). In patients with chronically ele vated 
natriuretic peptides, a significant increase should be noted above baseline.  
▪ Radiological evidence of pulmonary congestion  
▪ Non -invasive or invasive diagnostic evidence of clinically significant elevated 
left- or right -sided ventricular filling pressu re or low cardiac output. For 
example, echocardiographic criteria could include: E/e’ > 15  or D -dominant 
pulmonary venous inflow pattern, plethoric inferior vena cava with minimal 
collapse on inspi[INVESTIGATOR_118951] 
▪ Invasive diagnostic evidence with right heart cat heterization showing a 
pulmonary capi[INVESTIGATOR_47469] (pulmonary artery occlusion  pressure) • 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 56 of 75 
 ≥18 mmHg, central venous pressure ≥ 12 mmHg, or a cardiac  index < 2.2  
L/min/m2 
 
• The patient receives initiation or intensification of treatment specifically for heart failure , 
including at least ONE  of the following:  
 
o Augmentation in oral diuretic therapy  
o Intravenous diuretic, inotrope, or vasodilator therap y 
o Mechanical or surgical in tervention, including:  
▪ Mechanical circulatory support (e.g., intra -aortic balloon pump, ventricular 
assist device)  
▪ Mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis) Using 
available information, Heart Failure will be categorized bas ed on the following:  
• Left ventricular ejection fraction (LVEF)  
• Type  
• Etiology  
 
• An Urgent Heart Failure Visit is defined as an event that meets all of the following:  
 
▪ The patient has an urgent, unscheduled office/practice or emergency 
department visit for a primary diagnosis of heart failure , but not meeting the 
criteria for a heart failure  hospi[INVESTIGATOR_059].  
▪ All signs and symptoms for heart failure  hospi[INVESTIGATOR_059] (i.e., 3) symptoms; 4) 
physical examination findings/laboratory evidence of new or worsening heart 
failure, as indicated above) must be met  
▪ The patient receives initiation or intensification of treatment specifically for 
heart failure , as detailed in the above section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 57 of 75 
 20 APPENDIX B: KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ)  
 
Kansas City Cardiomyopathy Questionnaire (KCCQ)  
 
The following questions refer to your heart failure  and how it may affect your life.  Please read and 
complete the following questions.  There are no right or wrong answers.  Please mark the answer that 
best applies to you.  
1.   Heart failure  affects different people in different ways.  Some feel shortness of breath while 
others feel fatigue.  Please indicate how much you are limited by [CONTACT_119014]  (shortness of 
breath or fatigue) in your ability to do the following activities over the past 2 weeks .  
Activity  Extremely 
Limited  Quite a bit 
Limited  Moderatel y 
Limited  Slightly 
Limited  Not at all 
Limited  Limited for other 
reasons or did not 
do the activity  
Dressing yourself        
Showering/Bathing        
Walking 1 block on 
level ground        
Doing yardwork, 
housework or 
carrying groceries        
Climbing a flight of 
stairs without 
stoppi[INVESTIGATOR_007]        
Hurrying or jogging 
(as if to catch a bus)        
 
2.  Compared with [ADDRESS_132736] your symptoms of heart failure (shortness of breath, 
fatigue, or ankle swelling) changed?   
 
 My symptoms of heart failure  have become…  
Much worse  Slightly 
worse  Not changed  Slightly better  Much better  I’ve had no symptoms 
over the last 2 weeks  
      
 
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132737] swelling  in your feet, ankles or legs 
when you woke up in the morning?  
 
Every morning  [ADDRESS_132738] 2 weeks  
     
 
 
4.  Over the past 2 weeks , how much has swelling  in your feet, ankles or legs bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had no 
swelling  
      
 
 
5.  Over the past 2 weeks , on average, how many times has fatigue  limited your ability to do 
what you  want?  
All of the 
time  Several times 
per day  At least once 
a day  [ADDRESS_132739] 2 
weeks  
       
 
 
1.  Over the past 2 weeks,  how much has your  fatigue bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had 
no fatigue  
      
 
7. Over the past 2 weeks , on average, how many times has shortness of breath  limited your 
ability to do what you wanted?  
All of the 
time  Several times 
per day  At least once 
a day  [ADDRESS_132740] 2 
weeks  
       
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132741] 2 weeks,   how much has your shortness of breath  bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had no 
shortness of breath  
      
 
9.  Over the past [ADDRESS_132742] 3 pi[INVESTIGATOR_118952] ? 
 
Every night  [ADDRESS_132743] 2 weeks  
     
 
10.  Heart failure  symptoms can worsen for a number of reasons.  How sure are you that you know what 
to do, or whom to call, if your heart failure  gets worse?  
 
Not at all  sure  Not very  sure  Somewhat  sure  Mostly  sure  Completely  sure  
     
 
 
11.  How well do you understand what things you are able to do to keep your heart failure  symptoms 
from getting worse? (for example, weighing yourself, eating a low salt diet etc.)  
 
Do not understand  
at all  Do not understand 
very well  Somewhat 
understand  Mostly 
understand  Completely 
understand  
 
12.  Over  the past 2 weeks , how much has your heart failure  limited your enjoyment of life?  
 
It has extremely 
limited my 
enjoyment of life  It has limited  my 
enjoyment of life 
quite a bit  It has moderately  
limited my 
enjoyment of life  It has slightly  
limited my 
enjoyment of life  It has not limited  
my enjoyment of 
life at all  
     
 
 
DEFINE -HF Protocol Final v3.[ADDRESS_132744] it is right now , how 
would you feel about this?  
Not at all 
satisfied  Mostly 
dissatisfied  Somewhat 
satisfied  Mostly 
satisfied  Completely 
satisfied  
     
 
 
14.  Over the past [ADDRESS_132745] you felt discouraged or down in the dumps because of 
your heart failure ? 
I felt that way 
all of the time  I felt that way 
most of the time  I occasionally  
felt that way  I rarely  felt that 
way I never  felt that 
way 
     
 
15.  How much does your heart failure  affect your lifestyle?  Please indicate how your heart 
failure may have limited your participation in the following activities over the past [ADDRESS_132746] an X in one box on each line  
 
Activity   
Severely 
limited   
Limited  quite a 
bit  
Moderately 
limited   
Slightly 
limited   
Did not limit  
at all  Does not apply 
or did not do for 
other reasons  
Hobbies, 
recreational 
activities   
  
  
  
  
  
 
Working or doing 
household chores   
  
  
  
  
  
 
Visiting  family or 
friends out of your 
home     
  
  
  
 
Intimate 
relationships with 
loved ones   
  
  
  
  
  
 
Place an X in one box on each line  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 61 of 75 
 21 APPENDIX C: BIOMARKER SUBSTUDY  
Type 2 diabetes (DM) and prediabetes exacerbate the complications of all forms of cardiovascular 
disease, and particularly heart failure.1, [ADDRESS_132747] the myocardium, leading to increased 
left ventricular (LV) hy pertrophy, altered LV remodeling, and reduced systolic and diastolic function.3 In 
the presence of hypertension or ischemia/infarction, DM  worsens adverse LV remodeling and 
dysfunction, which results in worse heart failure (HF) symptoms and increased mortality.4-6   
The recently released EMPA -REG OUTCOME trial noted a 38% relative risk reduction of cardiovascular 
death  with empagliflozin, a SGLT -2 inhibitor, versus placebo in patients with diabetes and established 
CVD .7 Though the trial was predominantly of diabetic patients with coronary  artery disease, the majority 
of the benefit appeared to be due to the reduction in hospi[INVESTIGATOR_104732] (a 35% relative 
risk reduction ), and prevention of heart failure related and arrhythmia -related deaths.  The mechanism 
of action for such a dramatic benefit in prevention of HF and cardiovascular mortality is not well 
understood , but does not appear to be due to the glucose lowering effects of empagliflozin.  
It is therefore  likely that mechanisms  beyond glucose  lowering and diuresis  are behind the reduction in 
HF events and CV mortality with SGLT -2 inhibitors.8 We hypothesize that the majority of the benefit of 
SGLT -2 inhibitors in HF is due to a reduction in oxidative stress, (thus improving both sy stolic and 
diastolic function), improvement in endothelial function (thus decreasing vessel stiffness) and possible 
neurohormonal and anti -inflammatory effects.  Supporting this hypothesis are rat models where SGLT -2 
inhibition was shown to normalize endot helial function, reduce oxidative stress in aortic vessels, reverse 
a pro -inflammatory phenotype, and improve AGE/RAGE signaling all pathways of potential importance 
to a reduction in arterial stiffness.9  
The biomarker substudy will address the following Specific Aims:  
1. Specific Aim #1: To assess the impact of dapagliflozin vs. placebo on known markers of myocardial 
fibrosis/necrosis, inflammation, and oxidative stress in patients with chronic HF  with reduced systolic 
function  (with and without diabetes)  
 
We will m easure systemic biomarkers of oxidative stress: Uric Acid, Fibrosis: galectin -3 (Gal3 ), ST-2, 
myocyte necrosis: High sensitivity cardiac troponin T (hs -cTnT),  and inflammation: high -sensitivity C 
reactive protein  (hsCRP), interleukin -6 (Il-6). (See Appendix C Biomarker Summary Table ).  The change in 
biomarkers between 0, 6 and 12  weeks will be compared between dapaglif lozin and placebo.   
Anticipated results:  We hypothesize that multiple biomarkers reflecting dive rse biological  pathways 
would be significantly decreased in patients receiving dapaglif lozin vs. placebo.  Our overarching 
hypothesis is that patients taking dapaglif lozin for [ADDRESS_132748] a significantly greater reduction in 
biomarkers of oxidative stress (one of the most likely underlying mechanisms of benefit of SGLT -2 
inhibitors) than those on placebo.  
2. Specific Aim #2: Examine the relationship between biomarkers of myocardial fibrosis /necrosis, 
inflammation,  and oxidative stress and clinical outcomes, including heart failure specific biomarkers 
(BNP, NTproBNP), as well as patients’ symptoms and functional status (KCCQ and [ADDRESS_132749])  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 62 of 75 
 Linear regression will be employed with heart failure specific biomarkers (BNP, NTproBNP). KCCQ and 6 
minute walk, as dependent variables  (separate models); independent variables will include biomarker s 
of oxidative stress, fibrosis /necrosis, inflammation and other potential confounders; the bio markers will 
be included in separate models and chosen based on the strongest univariable relationships between 
biomarkers and the clinical outcomes.  
Anticipated results:   We hypothesize that those patients with the greatest clinical benefit (by [CONTACT_119015], 
NTpro BNP, KCCQ or 6 min walk) will be those with a significant reduction in pro inflammatory, fibrotic, 
and oxidative stress biomarkers.  
3. Specific Aim #3: Preserve residual blood specimens (banked biospecimens) for long -term storage so that 
evaluations for addi tional biomarkers or genetic analyses could be performed in the future.  
 
To protect subjects’ confidentiality, the banked biospecimens and data generated from them will be 
coded with the subject’s study ID number.  Samples will be kept in a secure storage area.  Data will be 
stored on password -protected computer systems. The key between the code and the subject’s personal 
identifiers will be held at the study site; the researchers using the biospecimens and data generated 
from them will not have access to t he key nor any personally identifying information.  
 
It is very unlikely that results generated from the banked biospecimens will have any clinical, diagnostic, 
or therapeutic implications for the individual study participants.  Subjects are notified in the  informed 
consent document that their results will not be given to them, to family members or other physicians; 
nor will they be recorded in the subject’s medical record.  
 
A research proposal would be submitted to the Saint Luke’s Hospi[INVESTIGATOR_118953] l of any future 
analysis that might be conducted on the banked biospecimens.  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 63 of 75 
  
 
 
 
 
 
  
 
 
 
Appendix C Biomarker Summary Table:   
Circulating 
biomarkers  Background, rationale, and measurement  
Inflammatory  
(IL-6, HS -CRP)  •  Several proinflammatory cytokines such as C -reactive protein (CRP), interleukine -6 
(IL-6) seem to play a role in the low -grade systemic inflammation observed in 
diabetics.  
• HS-CRP is increased in heart failure.  Higher levels are associated with feature s of 
more severe heart failure and are independently associated with mortality and 
morbidity s10 
Advanced glycation 
end-products  
(AGEs)  
(CML, sRAGE ) • AGEs (circulating carboxymethyl -lysine [CML] and soluble receptor for AGEs 
[sRAGE]) are products of nonen zymatic glycation and oxidation which are known to 
rapi[INVESTIGATOR_118954].11   
• In Mouse RAGE mediates inflammatory signaling, is involved in diabetic macro and 
microvascular complicati ons, and is associated with increased muscle, cartilage, and 
vascular stiffness.12-14 Given the adverse effects of AGEs i n diabetes, AGEs may play 
a particularly important role in the pathobiology of heart failure in diabetics  
Stress/Fibrosis  
(Gal-3, soluble ST2 ) • Galectin [ADDRESS_132750] been found to be 
significantly associated with higher risk of death in both acute decompensated heart 
failure and chronic heart failure populations.19 
•  Soluble ST2 signals the presence and severity of adverse cardiac remodeling and 
fibrosis. Its levels are elevated in both diabetics and heart failure with reduce ejection 
fraction, and prognosti c of morbidity and mortality.18 
Oxidative Stress  
(Uric Acid ) • In Mouse models SGLT -[ADDRESS_132751] demonstrated a decrease in uric 
acid.21 It is unclear whether the decrease in Uric Acid is through renal loss or truly 
by a d ecrease in oxidative stress.   
Myocardial 
Necrosis:  
(High sensitivity 
cardiac troponin T 
(hs-cTnT)  
 •  High‐sensitivity troponin assays represent an important advance with added 
sensitivity for cardiac myocyte necrosis , therefore allowing  risk stratification and 
prognostic information in stable disease states  such as chronic systolic heart failure. 
23, 24 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 64 of 75 
 References:  
1. Kannel WB and McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA . 
1979;241:2035 -8. 
2. Mak KH and Topol EJ. Emerging concepts in the management of acute myocardial infarction in 
patients with diabetes mellitus. J Am Coll Cardiol . 2000;35:563 -8. 
3. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rho ades 
ER and Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. 
Circulation . 2000;101:[ADDRESS_132752] of diabetes on survival following 
myocardial infarction in men vs women. The Framingham Study. JAMA . 1988;260:[ADDRESS_132753] BV. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventr icular 
structure and function in American Indians (the Strong Heart Study). Am J Cardiol . 2001;87:[ADDRESS_132754] of type 2 diabetes mellitus on left ventricular geometry and systolic 
function in hypertensive subjects: Hypertension Genetic Epi[INVESTIGATOR_118955] (HyperGEN) study. 
Circulation . 2001;103:102 -7. 
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, De vins T, Johansen OE, 
Woerle HJ, Broedl UC, Inzucchi SE and Investigators E -RO. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. The New England journal of medicine . 2015.  
8. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, H antel S, Espadero RM, Woerle HJ, Broedl UC 
and Johansen OE. SGLT -2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing 
outcome trials. Diabetes & vascular disease research . 2015;12:90 -100.  
9. Oelze M, Kroller -Schon S, Welschof P, Ja nsen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinssius E, 
Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, Munzel T and Daiber A. The 
sodium -glucose co -transporter 2 inhibitor empagliflozin improves diabetes -induced vascular dysfun ction 
in the streptozotocin diabetes rat model by [CONTACT_119016]. PloS one . 
2014;9:e112394.  
10. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, 
Glazer R, Cohn JN and Val -He FTI. C -reactive protein in heart failure: prognostic value and the effect of 
valsartan. Circulation . 2005;112:1428 -34. 
11. Yan SF, Ramasamy R, Naka Y and Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the 
macrovascular complications of diabetes and beyond. Circulation research . 2003;93:1159 -69. 
12. Aronson D. Cross -linking of glycated collagen in the pathogenes is of arterial and myocardial 
stiffening of aging and diabetes. J Hypertens . 2003;21:3 -12. 
13. Ulrich P and Cerami A. Protein glycation, diabetes, and aging. Recent progress in hormone research . 
2001;56:1 -21. 
14. Yan SF, Ramasamy R and Schmidt AM. Mechanis ms of disease: advanced glycation end -products and 
their receptor in inflammation and diabetes complications. Nature clinical practice Endocrinology & 
metabolism . 2008;4:[ADDRESS_132755] SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morga n JP, Sellke FW, Stillman 
IE, Epstein FH, Sukhatme VP and Karumanchi SA. Excess placental soluble fms -like tyrosine kinase 1 
(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin 
Invest . 2003;111:649 -58. 
16. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS and Walsh K. Vascular endothelial growth factor 
blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to 
pressure overload. Hypertension . 2006;47:887 -93. 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 65 of 75 
 17. Ky  B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB and Cappola TP. The vascular 
marker soluble fms -like tyrosine kinase 1 is associated with disease severity and adverse outcomes in 
chronic heart failure. J Am Coll Cardiol . 2011;58:386 -94. 
18. Bhardwaj A and Januzzi JL, Jr. ST2: a novel biomarker for heart failure. Expert review of molecular 
diagnostics . 2010;10:459 -64. 
19. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, Sharma UC, Bakker JA, Low AF, 19. Martinez A, Crijns 
HJ, MacRae CA, Menhe ere PP and Pi[INVESTIGATOR_118956]. Utility of amino -terminal pro -brain natriuretic peptide, 
galectin -3, and apelin for the evaluation of patients with acute heart failure. Journal of the American 
College of Cardiology . 2006;48:1217 -24. 
20. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H and 
Wollert KC. Serial measurement of growth -differentiation factor -15 in heart failure: relation to disease 
severity and prognosis in the Valsartan Heart Failure Trial. Circulation . 2010;122: 1387 -95. 
21. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W and 
Canagliflozin DIASG. Dose -ranging effects of canagliflozin, a sodium -glucose cotransporter 2 inhibitor, as 
add-on to metformin in subjects with type 2 diabet es. Diabetes care . 2012;35:1232 -8. 
22. Knight RK, Miall PA, Hawkins LA, Dacombe J, Edwards CR and Hamer J. Relation of plasma 
aldosterone concentration to diuretic treatment in patients with severe heart disease. British heart 
journal . 1979;42:316 -25. 
23. Apple FS, Collinson PO and Biomarkers ITFoCAoC. Analytical characteristics of high -sensitivity cardiac 
troponin assays. Clinical chemistry . 2012;58:54 -61. 
24. Twerenbold R, Jaffe A, Reichlin T, Reiter M and Mueller C. High -sensitive troponin T measurements : 
what do we gain and what are the challenges? European heart journal . 2012;33:579 -86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 66 of 75 
 22 APPENDIX D: ARR HYTHMIA SUBSTUDY  
 
Heart Failure (HF) is associated with significant morbidity and mortality, with overall 60 -day mortality 
among clinical trial patients hospi[INVESTIGATOR_118957] 10 percent.1 It has been 
demonstrated that patients with NYHA class I –III tend to die sudd enly whereas the death is usually due 
to refractory failure in those with Class IV symptomatology.2 Estimates from the  Framingham study 
show sudden cardiac death which occurs in 30 –50% of patients with heart failure.[ADDRESS_132756] been shown to decrease premature 
ventricular complexes (PVCs) and non -sustained ventricular tachycardia (NSVT), which have both been 
shown t o correlate with sudden cardiac death in HF patients.6 
The recently released EMPA -REG OUTCOME trial noted a 38% relative risk reduction of cardiovascular 
death with empagliflozin, a SGLT -2 inhibitor, versus placebo in patients with diabetes and established 
CVD.7 Though the trial was predominantly of diabe tic patients with coronary artery disease (an overall 
low risk population for arrhythmia and sudden cardiac death compared to HF patients), empagliflozin 
demonstrated a 31% relative risk reduction of sudden cardiac death compared to placebo.  
Atrial arrhyt hmias are also associated with significant morbidity and mortality amo ngst patients with 
HF.8  Numerous animal models and some small series of humans demonstrated a potential benefit of 
thiazolidinedione  (TZD) in reducing atrial fibrillation amongst diabetic  patients .9, [ADDRESS_132757] perhaps secondary to anti-inflammatory and antioxidant effects of 
TZDs.11 While the mechanism of benefit of SGLT -2 on cardiovascular outcomes is unknown  taking into 
consideration the aforeme ntioned improvement in cardiac death, sudden cardiac death, death due to 
worsening HF, and HF hospi[INVESTIGATOR_118958] . It is therefore that we hypothesize  dapaglif lozin might exert be neficial effects on 
atrial remodeling reducing AF burden among patients  with HF  (with an d without type 2 diabetes) .  
Arrhythmia sub study design:  
At screening visit ( -2 weeks) those likely to be enrolled will be given  the option to participate in the 
arrhy thmia sub study. If they elect to enroll they will wear  a CARDIOKEY  holter monitor for 14 days to 
establish a baseline.   The 14 -day holter will be repeated  at the 6 -week visit to compare change in 
arrhythmia  burden.  
When a patient has completed wearing the monitor for 14 days they will send the monitor in a pre paid 
package to Cardionet for processing.  The coordinating center (Saint Luke ’s Mid America Heart  Institute ) 
will have a portal with data from all study locations underneath it for data processing and interpretation. 
Each site will be assigned the necessary number of CARDIOKEY  devices , and replacement units ship 
automatically when a unit is enrolled w ith a patient.   These are shipped second -day air via UPS, so we 
can set it up so there are enough inventories at each site.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 67 of 75 
 Outcomes of sustained VT epi[INVESTIGATOR_1841] , non-sustained VT ( NSVT ) epi[INVESTIGATOR_1841] , VF epi[INVESTIGATOR_1841], atrial fibrillation, 
PVCs and PACs  will be compar ed between dapaglif lozin and placebo  (see representative  table ). 
Power Calculation  for decrease in PVCs/hour.  
Ramires et al reported a baseline PVC/hour burden of 65 +15, this amongst a cohort of NYHA class III 
patients.  After 16 weeks of spi[INVESTIGATOR_118959]/hour burden decreased to 17 +9.  Given that the 
patient population of DEFINE -HF population will be less “sick” (NYHA class II and III), we are predicting a 
baseline PVC burden of 50+15 per hour.  Assuming a 14% reduction in PVC per ho ur after 6 weeks of 
dapaglif lozin; 98 patients would be required in each cohort to achieve 90% power (see Appendix D Table 
1).  
Appendix D Table 1.  
Placebo (PVC/Hr)  Dapaglif lozin N for each arm  Power  
50[PHONE_2707][PHONE_2708]%  
50[PHONE_2709][PHONE_2710]%  
50[PHONE_2711][PHONE_2712]%  
50[PHONE_2713][PHONE_2714]%  
 
Ventricular arrhythmias  
 
 
 
 
 
Atrial arrhythmias  
 
 
 
 
P evaluated with Independent sample  t-test.  Outcomes  Dapaglif lozin  Placebo  P value  
VT epi[INVESTIGATOR_118960]  P value  
A fib burden     
PAC burden     
A fib epi[INVESTIGATOR_118961] -HF Protocol Final v3.0                                                                                                    Page 68 of 75 
 NSVT: non -sustained ventricular tachycardia, VF: ventricular fibrillation, VT: ventricular tachycardia, PVC: 
premature ventricular contractions , A fib : Atrial fibrillation  
 
Representative figure adapted from ( The American Journal of Cardiology, Volume 85, Issue 10, 2000, 
1207 –1211 ) 
 
 
 
 
 
 
 
 
 
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 69 of 75 
  
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 70 of 75 
  
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 71 of 75 
  
References:  
1.Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, Investigators I -H and Coordinators. 
Predischarge initiation of carvedilol in patients hospi[INVESTIGATOR_118962]: results of 
the Initiation Management Predischarge: Process f or Assessment of Carvedilol Therapy in Heart Failure 
(IMPACT -HF) trial. Journal of the American College of Cardiology . 2004;43:[ADDRESS_132758] in advanced heart failure. Circulation . 1989;80:1675 -80. 
3. Kannel WB, Plehn JF and Cupples LA. Cardiac failure and sudden death in the Framingham S tudy. 
American heart journal . 1988;115:[ADDRESS_132759] of 
spi[INVESTIGATOR_118963] c ardiomyopathy. The American journal of cardiology . 2000;85:[ADDRESS_132760] of carvedilol on survival in severe chronic heart failure. The New England journal of medicine . 
2001;344:[ADDRESS_132761], Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O and Perrone SV. 
Nonsustained ventricul ar tachycardia in severe heart failure. Independent marker of increased mortality 
due to sudden death. GESICA -GEMA Investigators. Circulation . 1996;94:3198 -203.  
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johans en OE, 
Woerle HJ, Broedl UC, Inzucchi SE and Investigators E -RO. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. The New England journal of medicine . 2015.  
8. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M,  Metra M, Torp -Pedersen C 
and Poole -Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on 
long -term treatment with beta -blockers: results from COMET. European heart journal . 2005;26:1303 -8. 
9. Korantzopoulos P, Kok koris S, Kountouris E, Protopsaltis I, Siogas K and Melidonis A. Regression of 
paroxysmal atrial fibrillation associated with thiazolidinedione therapy. International journal of 
cardiology . 2008;125:e51 -3. 
10. Anglade MW, Kluger J, White CM, Aberle J and C oleman CI. Thiazolidinedione use and post -operative 
atrial fibrillation: a US nested case -control study. Current medical research and opi[INVESTIGATOR_1649] . 2007;23:2849 -
55. 
11. Liu T, Korantzopoulos P, Li G and Li J. The potential role of thiazolidinediones in atrial f ibrillation. 
International journal of cardiology . 2008;128:129 -30. 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 72 of 75 
  
23   Appendix E: SensiVest Remote Dielectric Sensing ReDS™ to Assess Lung 
Fluid Volumes  (at selected sites)  
SensiVest utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military who used it to see inside buildings and to find survivors 
among rubble.  Sensible Medical has adapted the same  principles and created a vest that when worn 
sends low -power electromagnetic energy through the lungs, which decipher air content from fluid.1   Two 
sensors are attached to the body: one anteriorly on the chest and the other on the back of the patient. 
Each sensor both transmits and receives the energy either reflected from or transferred through the 
pulmonary tissue. The signal received reflects the dielectric properties of the section of the lung between 
the sensors.  Water has a very high dielectric coefficient while air in contrast has the lowest dielectric 
coefficient. These physical properties make pulmonary tissue ideal to sensitively quanti fy the ratio of fluid 
to air (or in the case of heart failure estimate volume status and pulmonary edema).[ADDRESS_132762] and correlating changes in ReDS 
values among porcine models of heart failure undergoing both fluid challenge and then diu resis. At 
selected  DEFINE -HF study sites  patients lung/fluid volume will be measured at randomization (0 weeks), 
6, [ADDRESS_132763] measurements preformed.  A number of exploratory endpoints will be assessed with 
this data:  
Specific Aim #1:  To assess the impact of dapaglifloz in vs. placebo on  lung fluid volumes  in patients with 
Hear t Failure with reduced systolic function.  
We will measure  sedentary baseline lung fluid volume by [CONTACT_119017] 0, 6, 12 and 13 -week office visits 
and compare values between dapagliflozin and placebo.  
Anticipated results:  We hypothesize that there will be  a significa ntly lower percentage of lung fluid in 
patients receiving dapagliflozin vs. placebo.  Similarly we hypothesize that on cessation of dapagliflozin  or 
placebo, lung fluid concentration will increase in patients treated with dapagliflozin to a gre ater extent 
than in those treated with placebo.  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 73 of 75 
 Specific Aim # 2: Examine the relationship between lung fluid volume and clinical outcomes, including 
heart failure specific biomarkers (BNP, NTproBNP), as well as patients’ symptoms and functional status 
(KCCQ and [ADDRESS_132764]), heart failure hospi[INVESTIGATOR_118964].  
Anticipated results:  We hypothesize that those patients with the greatest reductions in lung fluid volume 
will be those with the greatest clinical benefit (by  [CONTACT_119015], NTproBNP, KCCQ or 6 min walk).  
Specific Aim #3:  Examine the relationship between lung fluid volume and novel heart failure biomarkers 
Uric Acid, myeloperoxidase level (MPO), Fibrosis: galectin -3 (Gal3) , soluble ST -2, Myocyte necrosis: High 
sensitivity cardiac troponin T (hs -cTnT),  and Inflammation: high -sensitivity C reactive protein (hsCRP), 
interleukin -6 (Il-6).  
Anticipated results:  We hypothesize that those patients with the greatest reductions in lung fluid volu me 
will be those with a significant reduction in pro inflammatory, fibrotic, and oxidative stress biomarkers.  
 
References : 
1. http://sensible -medical.com/ . 1/26/2015  
2. Rappaport D. Noninvasive Monitoring of Pulmonary Congestion Using a Remote Dielectric Sensing 
(ReDS) System: A Prospective Single -Arm Study in Patients Suffering from Heart Failure. Journal of 
cardiac failure; 18(8):S61 doi: 10.1016/j.cardfail.2012.06.207[published Online First: Ep ub Date]|.  
3. Amir O, Rappaport D, Zafrir B, et al. A novel approach to monitoring pulmonary congestion in heart 
failure: initial animal and clinical experiences using remote dielectric sensing technology. Congestive 
heart failure 2013; 19(3):149 -55 doi: 10 .1111/chf.[ZIP_CODE][published Online First: Epub Date]|.  
4. Abraham WT, Amir O, Weinstein JM, et al. Remote Dielectric Sensing (ReDS&#x2122;) -Guided Patient 
Management of Ambulatory Heart Failure Patients Reduces Rehospi[INVESTIGATOR_118965]. Journal of cardiac 
failure; 21(8):S77 doi: 10.1016/j.cardfail.2015.06.240[published Online First: Epub Date]|.  
5. Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart 
Failure Patients (SMILE™). Clinicaltrialsgov 2015; 
https://clinicalt rials.gov/ct2/show/record/[STUDY_ID_REMOVED]?term=sensible&rank=1   
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 74 of 75 
   
 
 
 
 
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 75 of 75 
  
 
24   APPENDIX F: PRINCIPAL INVESTIGATOR [INVESTIGATOR_118966] b Iomarkers i N patiEnts with 
Heart Failure (DEFINE -HF) 
 
  
 
I agree to the terms of this study protocol. I will conduct the study according to the procedures 
specified herein, and according to the principles of Good Clinical Practice and local regulations.  
 
 
Site Number:  ____________  
  
Signature:  
   
 [CONTACT_119022]  
 
_____________________________________  
Principal Investigator [CONTACT_5627] (print or type)  
 Date  
   
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approval. Investigators are cautioned that the 
information in this protocol may be subject to change and revision.  
 